


10/520,567

=>

Uploading C:\Program Files\Stnexp\Queries\10520567.str



chain nodes :
13 14
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 17 18 19 20 21 22
chain bonds :
2-13 9-13 14-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22
18-19 19-20 20-21 21-22
exact/norm bonds :
2-13 9-13 14-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 17-18 17-22
18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 7 : 17 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 17:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom
Generic attributes :
14:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : 2 or more
Type of Ring System : Monocyclic

Element Count :
Node 14: Limited
C,C3
N,N2

10/520,567


O,00
S,S0

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 18:15:59 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2639 TO ITERATE

75.8% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

13 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 49699 TO 55861
PROJECTED ANSWERS: 95 TO 591

10/520,567

L2 13 SEA SSS SAM L1

=> => s l1 sss ful

FULL SEARCH INITIATED 18:17:07 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 55056 TO ITERATE

100.0% PROCESSED 55056 ITERATIONS


648 ANSWERS

SEARCH TIME: 00.00.01

L3 648 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10520567 (sub).str



chain nodes :

13 14

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 18 19 20 21 22 23 24 25 26 27 28
29 30 31 32

chain bonds :

2-13 9-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 18-19 18-22
19-20 20-21 21-22 23-24 23-27 24-25 25-26 26-27 28-29 28-32 29-30 30-31
31-32

exact/norm bonds :

2-13 9-13 18-19 18-22 19-20 20-21 21-22 23-24 23-27 24-25 25-26 26-27
28-29 28-32 29-30 30-31 31-32

10/520,567

normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12
isolated ring systems :
containing 1 : 7 :

G1:[*1],[*2],[*3]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:CLASS 14:Atom 15:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom
31:Atom 32:Atom
Element Count :
Node 14: Limited
C,C3
N,N2
O,O0
S,S0

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l4 sub=l3 sss sam

SAMPLE SUBSET SEARCH INITIATED 18:21:49 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED 16 ITERATIONS 16 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	80 TO	560
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	80 TO	560

L5 16 SEA SUB=L3 SSS SAM L4

=> => d his

(FILE 'HOME' ENTERED AT 18:15:15 ON 15 SEP 2007)

FILE 'REGISTRY' ENTERED AT 18:15:31 ON 15 SEP 2007

L1 STRUCTURE UPLOADED
L2 13 S L1 SSS SAM
L3 648 S L1 SSS FUL
L4 STRUCTURE UPLOADED
L5 16 S L4 SSS SAM SUB=L3
L6 178 S L4 SSS FUL SUB=L3

10/520,567

```
=> s 13 not 16
L7          470 L3 NOT L6

=> => s 17
L8          17 L7

=> d 18 1-17 bib,ab,hitstr
```

L8 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2007:227055 CAPLUS
 DN 146:274390
 TI Pyrimidinyl-pyrazole inhibitors of Aurora kinases and their preparation,
 pharmaceutical compositions and use in the treatment of cell proliferative
 diseases
 IN Adams, Jerry Leroy; Faitg, Thomas H.; Ralph, Jeffrey M.; Silva, Domingos
 J.
 PA Smithkline Beecham Corporation, USA
 SO PCT Int. Appl., 99pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007024843	A2	20070301	WO 2006-US32746	20060823
	WO 2007024843	A3	20070809		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2005-711979P	P	20050826		


OS MARPAT 146:274390

AB The invention provides a compound represented by formula I: or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof. Comps. of formula I wherein R1 is (un)substituted Ph, heteroaryl, C1-6 alkyl, C3-6 cycloalkyl, and NH2 and derivs.; R2 and R3 are independently H, halo, C1-3 alkyl, and O-C1-3 alkyl; R4 a substituents on the nitrogen atoms of pyrazole, is H, (un)substituted C1-6 alkyl, C3-6 cycloalkyl, (un)substituted CO-C1-6 alkyl, CONH2 and derivs., SO2-C1-6 alkyl, etc.; R5, R5' and R6 are independently H, (un)substituted C1-6 alkyl, substituted NHCO-C1-6 alkyl, (un)substituted O-C1-6 alkyl, NH2 and derivative, and OH; and their pharmaceutically acceptable salts, solvates and combinations thereof, are claimed. The invention also relates to a composition comprising the compound of formula I and diluents, carriers, or excipients. Furthermore, the invention relates to a method of treating a disease of cell proliferation comprising administering to a patient in need thereof a pharmaceutically effective amount of the compound of formula I or a salt thereof, or a solvate thereof, or a combination thereof. Example compound II was prepared by amination of N-(4-[4-[2-(methylsulfonyl)-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl)benzamide with 3-[2-(4-morpholinyl)ethyl]aniline. All the invention compound were evaluated for their Aurora A and Aurora B kinase inhibitory activity. From the assay, it was determined that the invention compds. exhibited IC50 values of less than 10 μ M against Aurora kinase A and B.

IT 927653-02-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of pyrimidinylpyrazoles as Aurora kinase inhibitors useful in the treatment of proliferative diseases)

RN 927653-02-9 CAPLUS
 CN 1-Pyrrolidinecarboxamide, N-[4-[4-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-1-(2-hydroxyethyl)-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




IT 927652-49-1P 927652-50-4P 927652-51-5P
 927652-52-6P 927652-53-7P 927652-54-8P
 927652-55-9P 927652-56-0P 927652-57-1P
 927652-58-2P 927652-59-3P 927652-60-6P
 927652-61-7P 927652-62-8P 927652-63-9P
 927652-64-0P 927652-65-1P 927652-66-2P
 927652-67-3P 927652-68-4P 927652-69-5P
 927652-70-8P 927652-71-9P 927652-72-0P
 927652-73-1P 927652-74-2P 927652-75-3P
 927652-76-4P 927652-77-5P 927652-78-6P
 927652-79-7P 927652-80-0P 927652-81-1P
 927652-82-2P 927652-83-3P 927652-84-4P
 927652-85-5P 927652-86-6P 927652-87-7P
 927652-88-8P 927652-89-9P 927652-90-2P
 927652-91-3P 927652-92-4P 927652-93-5P
 927652-94-6P 927652-95-7P 927652-96-8P
 927652-97-9P 927652-98-0P 927652-99-1P
 927653-00-7P 927653-01-8P 927653-03-0P
 927653-04-1P 927653-05-2P 927653-06-3P
 927653-07-4P 927653-08-5P 927653-09-6P
 927653-10-9P 927653-11-0P 927653-12-1P
 927653-13-2P 927653-14-3P 927653-15-4P
 927653-16-5P 927653-17-6P 927653-18-7P
 927653-19-8P 927653-20-1P 927653-21-2P
 927653-22-3P 927653-23-4P 927653-24-5P
 927653-25-6P 927653-26-7P 927653-27-8P
 927653-28-9P 927653-29-0P 927653-30-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyrimidinylpyrazoles as Aurora kinase inhibitors useful in the treatment of proliferative diseases)

RN 927652-49-1 CAPLUS
 CN Benzamide, N-[4-[4-[2-[(3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-50-4 CAPLUS

CN Benzamide, N-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]- (CA INDEX NAME)




RN 927652-51-5 CAPLUS


CN Benzamide, N-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)



RN 927652-52-6 CAPLUS
 CN Benzamide, N-[4-[4-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-53-7 CAPLUS
 CN Benzamide, N-[4-[4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-54-8 CAPLUS

CN Benzamide, N-[4-[4-[2-[[3-[[2-(dimethylamino)acetyl]amino]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-55-9 CAPLUS

CN Benzamide, N-[4-[4-[2-[[3-(4-morpholinylmethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-56-0 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-57-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)



RN 927652-58-2 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)



RN 927652-59-3 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)

10/520,567




RN 927652-60-6 CAPLUS

CN Benzamide, N-[4-[1-methyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]- (CA INDEX NAME)




RN 927652-61-7 CAPLUS

CN Benzamide, N-[4-[1-methyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-62-8 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-methyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]- (CA INDEX NAME)




RN 927652-63-9 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-methyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-64-0 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-ethyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]- (CA INDEX NAME)




RN 927652-65-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-ethyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-66-2 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-67-3 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-68-4 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)




RN 927652-69-5 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-70-8 CAPLUS

CN Urea, N-ethyl-N'-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]- (CA INDEX NAME)




RN 927652-71-9 CAPLUS

CN Urea, N-ethyl-N'-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)



RN 927652-72-0 CAPLUS


CN Urea, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-N'-propyl- (CA INDEX NAME)



RN 927652-73-1 CAPLUS


CN Urea, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-N'-propyl- (CA INDEX NAME)

10/520,567




RN 927652-74-2 CAPLUS

CN Urea, N-cyclopropyl-N'-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)




RN 927652-75-3 CAPLUS

CN Urea, N-cyclopropyl-N'-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)



RN 927652-76-4 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-(1-methylethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)



RN 927652-77-5 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-(1-methylethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)

10/520,567



RN 927652-78-6 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)



RN 927652-79-7 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)

10/520,567




RN 927652-80-0 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-81-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(2-methoxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-82-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(2-methoxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)




RN 927652-83-3 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(2-methylpropyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-84-4 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(2-methylpropyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)




RN 927652-85-5 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(methylsulfonyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927652-86-6 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)




RN 927652-87-7 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-88-8 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-89-9 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 3-[4-[(cyclopropylcarbonyl)amino]phenyl]-N-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927652-90-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-(3-hydroxypropyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)



RN 927652-91-3 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-(3-hydroxypropyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-
(CA INDEX NAME)



RN 927652-92-4 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[1-[(2S)-2,3-dihydroxypropyl]-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 927652-93-5 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[1-[(2R)-2,3-dihydroxypropyl]-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 927652-94-6 CAPLUS


CN 1-Pyrrolidinecarboxamide, N-[4-[1-(3-hydroxypropyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)



RN 927652-95-7 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-[(2R)-2,3-dihydroxypropyl]-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 927652-96-8 CAPLUS


CN 1-Pyrrolidinecarboxamide, N-[4-[1-[(2S)-2,3-dihydroxypropyl]-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 927652-97-9 CAPLUS

CN Urea, N,N-diethyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927652-98-0 CAPLUS

CN Urea, N'-[4-[1-(2-hydroxyethyl)-4-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 927652-99-1 CAPLUS

CN Urea, N'-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-N,N-dimethyl- (CA INDEX NAME)




RN 927653-00-7 CAPLUS

CN Urea, N,N-diethyl-N'-[4-[1-methyl-4-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927653-01-8 CAPLUS

CN Urea, N,N-dimethyl-N'-[4-[1-methyl-4-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927653-03-0 CAPLUS

CN Urea, N-cyclopropyl-N'-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927653-04-1 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-(CA INDEX NAME)




RN 927653-05-2 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-(CA INDEX NAME)



RN 927653-06-3 CAPLUS


CN Urea, N-cyclopropyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-2-methylphenyl]- (CA INDEX NAME)



RN 927653-07-4 CAPLUS


CN Urea, N,N-diethyl-N'-[4-[4-[2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]-1-methyl-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)

10/520,567



RN 927653-08-5 CAPLUS


CN Urea, N,N-diethyl-N'-[4-[1-methyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)



RN 927653-09-6 CAPLUS


CN Urea, N-ethyl-N'-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)

10/520,567




RN 927653-10-9 CAPLUS

CN Urea, N,N-diethyl-N'-[4-[4-[2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-4-pyrimidinyl]-1-methyl-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927653-11-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927653-12-1 CAPLUS

CN Urea, N,N-dimethyl-N'-[4-[1-methyl-4-[2-[[3-[2-(4-morpholinylethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927653-13-2 CAPLUS

CN Urea, N-ethyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[2-(4-morpholinylethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-2-methylphenyl]-
(CA INDEX NAME)




RN 927653-14-3 CAPLUS

CN Urea, N,N-diethyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927653-15-4 CAPLUS

CN Urea, N,N-diethyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-
(CA INDEX NAME)




RN 927653-16-5 CAPLUS

CN Urea, N-cyclopropyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-2-methoxyphenyl]- (CA INDEX NAME)




RN 927653-17-6 CAPLUS

CN Urea, N-cyclopropyl-N'-[4-[1-(2-hydroxyethyl)-4-[2-[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927653-18-7 CAPLUS

CN Urea, N-methyl-N'-[4-[1-methyl-4-[2-[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927653-19-8 CAPLUS

CN Urea, N-[4-[4-[2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-4-pyrimidinyl]-1-methyl-1H-pyrazol-3-yl]phenyl]-N'-methyl- (CA INDEX NAME)




RN 927653-20-1 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[4-[2-[[3-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-4-pyrimidinyl]-1-methyl-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927653-21-2 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-methyl-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




RN 927653-22-3 CAPLUS

CN 1H-Pyrazole-1-acetic acid, 4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-3-[4-[(1-pyrrolidinylcarbonyl)amino]phenyl]- (CA INDEX NAME)




RN 927653-23-4 CAPLUS


CN 1H-Pyrazole-1-acetic acid, 3-[4-[[[(ethylamino)carbonyl]amino]phenyl]-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN	927653-24-5	CAPLUS
CN	1H-Pyrazole-1-carboxamide, N-ethyl-3-[4-[[(ethylamino) carbonyl] amino] phenyl 1]-4-[2-[3-[2-(4-morpholinyl) ethyl] phenyl] amino]-4-pyrimidinyl]- (CA INDEX NAME)	




RN 927653-25-6 CAPLUS.
CN 1H-Pyrazole-1-acetic acid, 3-[4-[[(dimethylamino)carbonyl]amino]phenyl]-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-26-7 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]-2-fluorophenyl]- (CA INDEX NAME)




RN 927653-27-8 CAPLUS


CN 1-Pyrrolidinecarboxamide, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]-2-fluorophenyl]- (CA INDEX NAME)



RN 927653-28-9 CAPLUS
 CN Propanamide, N-[4-[4-[2-[[3-[[4-(2-hydroxyethyl)-1-piperazinyl]methyl]phenyl]amino]-4-pyrimidinyl]-1-methyl-1H-pyrazol-3-yl]phenyl]-2,2-dimethyl- (CA INDEX NAME)




RN 927653-29-0 CAPLUS
 CN Propanamide, 2,2-dimethyl-N-[4-[1-methyl-4-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)



RN 927653-30-3 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[4-[4-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-3-yl]phenyl]- (CA INDEX NAME)




IT 927653-41-6P 927653-42-7P 927653-43-8P
 927653-44-9P 927653-54-1P 927653-55-2P
 927653-56-3P 927653-57-4P 927653-58-5P
 927653-59-6P 927653-60-9P 927653-61-0P
 927653-62-1P 927653-63-2P 927653-64-3P
 927653-65-4P 927653-66-5P 927653-67-6P
 927653-68-7P 927653-69-8P 927653-70-1P
 927653-71-2P 927653-72-3P 927653-73-4P
 927653-74-5P 927653-75-6P 927653-76-7P
 927653-77-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidinylpyrazoles as Aurora kinase inhibitors useful in the treatment of proliferative diseases)


RN 927653-41-6 CAPLUS

CN Carbamic acid, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 927653-42-7 CAPLUS

CN Carbamic acid, N-[4-[1-ethyl-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-5-yl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 927653-43-8 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(4-aminophenyl)-1-ethyl-1H-pyrazol-4-yl]-N-[3-[2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)



10/520,567


RN 927653-44-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-aminophenyl)-1-ethyl-1H-pyrazol-4-yl]-N-[3-[2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)




RN 927653-54-1 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]-3-(4-nitrophenyl)- (CA INDEX NAME)




RN 927653-55-2 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-nitrophenyl)-4-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-56-3 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]-3-(4-nitrophenyl)- (CA INDEX NAME)




RN 927653-57-4 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(3-methyl-4-nitrophenyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-58-5 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(3-methoxy-4-nitrophenyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-59-6 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-[2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]-3-(4-nitrophenyl)- (CA INDEX NAME)




RN 927653-60-9 CAPLUS

CN 1H-Pyrazole-1-ethanol, 4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-3-(4-nitrophenyl)- (CA INDEX NAME)




RN 927653-61-0 CAPLUS

1-Piperazineethanol, 4-[3-[[4-[1-methyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 927653-62-1 CAPLUS

2-Pyrimidinamine, 4-[1-methyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-N-[3-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 927653-63-2 CAPLUS

RN	927853-83-2	CAFL03
CN	1-Piperazineethanol, 4-[[3-[[4-[1-methyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]methyl]-	(CA INDEX NAME)




RN 927653-64-3 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-N-[3-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 927653-65-4 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-3-(4-nitrophenyl)-1H-pyrazol-4-yl]-N-[3-[2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)




RN 927653-66-5 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-aminophenyl)-4-[2-[(3-fluorophenyl)amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-67-6 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-aminophenyl)-4-[2-[[3-(1-pyrrolidinylmethyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-68-7 CAPLUS


CN 1H-Pyrazole-1-ethanol, 3-(4-aminophenyl)-4-[2-[[3-(2-(4-morpholinylethyl)phenyl]amino)-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-69-8 CAPLUS
 CN 1H-Pyrazole-1-ethanol, 3-(4-amino-3-methylphenyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)



RN 927653-70-1 CAPLUS
 CN 1H-Pyrazole-1-ethanol, 3-(4-amino-3-methoxyphenyl)-4-[2-[[3-[2-(4-morpholinyl)ethyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-71-2 CAPLUS
 CN 1H-Pyrazole-1-ethanol, 3-(4-aminophenyl)-4-[2-[[3-[(4-methyl-1-piperazinyl)methyl]phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-72-3 CAPLUS

CN 1H-Pyrazole-1-ethanol, 3-(4-aminophenyl)-4-[2-[[3-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 927653-73-4 CAPLUS

CN 1-Piperazineethanol, 4-[3-[[4-[3-(4-aminophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (CA INDEX NAME)




RN 927653-74-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-aminophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[3-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)




RN 927653-75-6 CAPLUS

CN 1-Piperazineethanol, 4-[[3-[[4-[3-(4-aminophenyl)-1-methyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]methyl]- (CA INDEX NAME)




RN 927653-76-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-aminophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[3-(4-methyl-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 927653-77-8 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(4-aminophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[3-[2-(4-morpholinyl)ethyl]phenyl]- (CA INDEX NAME)



L8 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2006:365409 CAPLUS
 DN 144:390939
 TI Preparation of azolyldihydroxyalkanoates and lactones thereof as inhibitors of MAP kinase and/or HMG-CoA reductase for the treatment of inflammation
 IN Griffin, John; Lanza, Guido; Yu, Jessen
 PA USA
 SO U.S. Pat. Appl. Publ., 126 pp., Cont.-in-part of U.S. Ser. No. 118,113.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006084695	A1	20060420	US 2005-262521	20051028
	US 2005272770	A1	20051208	US 2005-118090	20050429
	US 2005282883	A1	20051222	US 2005-118113	20050429
	US 2005288306	A1	20051229	US 2005-118064	20050429
	US 7163945	B2	20070116		
	US 2006111436	A1	20060525	US 2005-118098	20050429
	EP 1755607	A2	20070228	EP 2005-818178	20050429
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	US 2007004758	A1	20070104	US 2006-469417	20060831
	US 2007015779	A1	20070118	US 2006-469419	20060831
	IN 2006DN06868	A	20070831	IN 2006-DN6868	20061117
PRAI	US 2004-567118P	P	20040429		
	US 2004-630683P	P	20041123		
	US 2004-630684P	P	20041123		
	US 2005-118113	A2	20050429		
	US 2005-118064	A1	20050429		
	US 2005-118065	A1	20050429		
	WO 2005-US14843	W	20050429		
OS	MARPAT 144:390939				
AB	<p>Analogs of atorvastatin and its lactones I and II [wherein A = covalent bond, methylene, ethylene, etc.; X = lipophilic moiety; Y = H or lower alkyl; Z = H or OH] and salts of II were prepared as inhibitors of MAP kinase and/or HMG-CoA reductase. Thus, atorvastatin calcium in EtOAc was treated with aqueous NaHSO₄ to give atorvastatin acid, which was heated in PhMe at 60° for 40 h to give atorvastatin lactone in 46% yield. The latter inhibited p38 MAP kinase with IC₅₀ = 20 μM. Therefore, I and their pharmaceutical comps. are useful for the treatment of inflammation.</p>				
IT	<p>869961-76-2P 869961-77-3P 869961-80-8P 869961-98-8P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of azolyldihydroxyalkanoates and lactones thereof as inhibitors of MAP kinase and/or HMG-CoA reductase for treatment of inflammation)</p>				
RN	869961-76-2 CAPLUS				
CN	<p>6-Heptenoic acid, 7-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (9CI) (CA INDEX NAME)</p>				


Absolute stereochemistry.
 Double bond geometry as shown.



● 1/2 Ca


RN 869961-77-3 CAPLUS
 CN 2H-Pyran-2-one, 6-[(1E)-2-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



RN 869961-80-8 CAPLUS
 CN 1H-Pyrazole-4-heptanoic acid, β,δ-dihydroxy-3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-, calcium salt (2:1), (βR,δR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 1/2 Ca


RN 869961-98-8 CAPLUS
 CN 6-Heptenoic acid, 3,5-dihydroxy-7-[1-[2-(phenylamino)-4-pyrimidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-, calcium salt (2:1), (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



● 1/2 Ca


IT 869961-73-9P 869961-74-0P 869961-75-1P
 869961-78-4P 869961-79-5P 869961-95-5P
 869961-96-6P 869961-97-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of azolyldihydroxyalkanoates and lactones thereof as inhibitors of MAP kinase and/or HMG-CoA reductase for treatment of inflammation)
 RN 869961-73-9 CAPLUS
 CN 2-Pyrimidinamine, 4-(4-bromo-3,5-diphenyl-1H-pyrazol-1-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 869961-74-0 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]ethenyl]-2,2-dimethyl-, ethyl ester, (4R,6S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 869961-75-1 CAPLUS

CN 6-Heptenoic acid, 7-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 869961-78-4 CAPLUS

CN 1H-Pyrazole-4-heptanoic acid, β,δ -dihydroxy-3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-, ethyl ester, ($\beta R,\delta R$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869961-79-5 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869961-95-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-bromo-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 869961-96-6 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 2,2-dimethyl-6-[(1E)-2-[1-[2-(phenylamino)-4-pyrimidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]ethenyl]-, ethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 869961-97-7 CAPLUS

CN 6-Heptenoic acid, 3,5-dihydroxy-7-[1-[2-(phenylamino)-4-pyrimidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-, ethyl ester, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10/520,567



L8 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1345046 CAPLUS
 DN 144:69823
 TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
 IN Naraian, Ashok S.; Clare, Michael; Collins, Paul W.; Crich, Joyce Zuowu;
 Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.;
 Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi; Naing, Win; Walker, John; Yang, Syaulan
 PA Pharmacia Corporation, USA
 SO U.S., 548 pp.
 CODEN: USXXAM

*Same as
#11*

DT Patent
 LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6979686	B1	20051227	US 2001-21780	20011207
	AU 2003200580	A1	20030501	AU 2003-200580	20030217
	US 7071198	B2	20060704	US 2004-840734	20040505
	US 2007078146	A1	20070405		
PRAI	US 1997-47570P	P	19970522		
	AU 1998-75883	A3	19980522		
	US 1998-196623	A2	19981120		
	US 2000-513351	A3	20000224		
	US 2001-21780	A3	20011207		

OS MARPAT 144:69823

AB Title compds. [I; R1 = H, OH, NH₂, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, mercapto, aryl, heterocyclyl, etc.; R3 = (un)substituted pyridinyl, pyrimidinyl, quinolinyl, etc.; R4 = H, alkyl, (un)substituted Ph, etc.; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R3CH₂COME (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C₆H₃CHO to give the butenone (80%), which was cyclocondensed with TsNHNH₂ to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC₅₀ of 4.6 μ M and inhibited tumor necrosis factor α (TNF α) and interleukin 1 β (IL-1 β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC₅₀ of 0.5 μ M. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNF α . The pharmaceutical compns. comprising the compound I are disclosed.


IT 271574-63-1P 271574-64-2P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 271574-63-1 CAPLUS


CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/520,567



RN 271574-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 87 THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:1242867 CAPLUS
 DN 144:6807
 TI Preparation of azolyldihydroxyalkanoates and lactones thereof as
 inhibitors of MAP kinase and/or HMG-CoA reductase.
 IN Griffin, John; Lanza, Guido; Yu, Jessen
 PA USA
 SO U.S. Pat. Appl. Publ., 129 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005261354	A1	20051124	US 2005-118066	20050429
	US 7183285	B2	20070227		
	US 2005272770	A1	20051208	US 2005-118090	20050429
	US 2005277653	A1	20051215	US 2005-118065	20050429
	US 7199126	B2	20070403		
	US 2005288306	A1	20051229	US 2005-118064	20050429
	US 7163945	B2	20070116		
	WO 2006028524	A2	20060316	WO 2005-US14843	20050429
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 2006111436	A1	20060525	US 2005-118098	20050429
	EP 1755607	A2	20070228	EP 2005-818178	20050429
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
	US 2007004758	A1	20070104	US 2006-469417	20060831
	US 2007015779	A1	20070118	US 2006-469419	20060831
	IN 2006DN06868	A	20070831	IN 2006-DN6868	20061117
PRAI	US 2004-567118P	P	20040429		
	US 2004-630683P	P	20041123		
	US 2004-630684P	P	20041123		
	US 2005-118064	A1	20050429		
	US 2005-118065	A1	20050429		
	WO 2005-US14843	W	20050429		
OS	MARPAT 144:6807				
AB	Title compds. e.g. [I, II, III; R1 = Q1, Q2; n = 0, any integer; R2 = (substituted) alkyl, aryl, heteroaryl; R3 = any substituent; R4 = (substituted) pyrimidinyl, pyridyl, imidazolyl; R5 = (substituted) aryl, heteroaryl; and salts thereof], were prepared Thus, atorvastatin calcium in EtOAc was treated with aqueous NaHSO4 to give atorvastatin acid, which was heated in PhMe at 60° for 40 h to give 46% atorvastatin lactone. The latter inhibited p38 MAP kinase with IC50 = 20 µM.				
IT	869961-76-2P 869961-77-3P 869961-80-8P 869961-98-8P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES				

(Uses)


(preparation of azolyldihydroxyalkanoates and lactones thereof as inhibitors of MAP kinase and/or HMG-CoA reductase)

RN 869961-76-2 CAPLUS

CN 6-Heptenoic acid, 7-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● 1/2 Ca

RN 869961-77-3 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 869961-80-8 CAPLUS

CN 1H-Pyrazole-4-heptanoic acid, β,δ -dihydroxy-3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-, calcium salt (2:1), (β R, δ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 1/2 Ca

RN 869961-98-8 CAPLUS

CN 6-Heptenoic acid, 3,5-dihydroxy-7-[1-[2-(phenylamino)-4-pyrimidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-, calcium salt (2:1), (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



● 1/2 Ca

IT 869961-73-9P 869961-74-0P 869961-75-1P

869961-78-4P 869961-79-5P 869961-95-5P


869961-96-6P 869961-97-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of azolyldihydroxyalkanoates and lactones thereof as inhibitors of MAP kinase and/or HMG-CoA reductase)

RN 869961-73-9 CAPLUS


CN 2-Pyrimidinamine, 4-(4-bromo-3,5-diphenyl-1H-pyrazol-1-yl)-N-phenyl- (9CI) (CA INDEX NAME)



RN 869961-74-0 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]ethenyl]-2,2-dimethyl-, ethyl ester, (4R,6S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 869961-75-1 CAPLUS

CN 6-Heptenoic acid, 7-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.



RN 869961-78-4 CAPLUS

CN 1H-Pyrazole-4-heptanoic acid, β,δ -dihydroxy-3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-, ethyl ester, ($\beta R,\delta R$)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 869961-79-5 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[3,5-diphenyl-1-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-4-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 869961-95-5 CAPLUS


CN 2-Pyrimidinamine, 4-[4-bromo-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 869961-96-6 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 2,2-dimethyl-6-[(1E)-2-[1-[2-(phenylamino)-4-pyrimidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]ethenyl]-, ethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 869961-97-7 CAPLUS

CN 6-Heptenoic acid, 3,5-dihydroxy-7-[1-[2-(phenylamino)-4-pyrimidinyl]-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-, ethyl ester, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

10/520,567




RE.CNT 110 THERE ARE 110 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AU Pillonel, Christian
CS Syngenta Crop Protection AG, Basel, CH-4002, Switz.
SO Pest Management Science (2005), 61(11), 1069-1076
CODEN: PMSCFC; ISSN: 1526-498X
PB John Wiley & Sons Ltd.


DT Journal
LA English
AB The effects of diverse phenylaminopyrimidines (PAP), namely PAP-pyridines (type A), PAP-pyrazoles (type B) and PAP-thiazoles (type C), on *Neurospora crassa* has been investigated. Type A strongly inhibit the in vitro growth of *N. crassa*, whereas types B and C are much less active. A significant correlation was observed between the *Neurospora* growth inhibition and the intrinsic activity of type A compds. on the cyclin-dependent protein kinase p34CDC2 of starfish, suggesting that the target of phenylaminopyrimidines in fungi is a cyclin-dependent protein kinase (CDK). The phenylaminopyrimidine-binding CDKs Phoss (major band) and CDC2 (minor band) involved in phosphorus uptake, glycogen synthesis and the cell cycle were identified from *N. crassa* by affinity chromatog. on phenylaminopyrimidine-sepharose. Comparative expts. with different protein kinases revealed the importance of the side chain of phenylaminopyrimidines for their target selectivity. A type B compound was found to selectively inhibit the MAP-kinase OS-2 involved in the osmoregulatory pathway of *Neurospora*.

IT 541507-63-5 541507-74-8 541507-75-9
541507-90-8
RL: BSU (Biological study, unclassified); BUU (Biological use,
unclassified); BIOL (Biological study); USES (Uses
(phenylaminopyrimidines as antifungal protein kinase inhibitors))

RN	541507-63-5	CAPLUS
CN	Benzenemethanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- α,α -dimethyl- (9CI) (CA INDEX NAME)	




RN	541507-74-8	CAPLUS		
CN	2-Pyrimidinamine, N-phenyl-4-(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)			




RN 541507-75-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-phenyl- (9CI)
(CA INDEX NAME)



RN 541507-90-8 CAPLUS

CN Ethanone, 1-[3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:673285 CAPLUS
 DN 143:172889
 TI Preparation of pyrazolyl-pyrimidinyl-amine derivatives as IGF-1R inhibitors
 IN Garcia-Echeverria, Carlos
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005068452	A1	20050728	WO 2005-EP93	20050107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205118	A1	20050728	AU 2005-205118	20050107
CA 2551948	A1	20050728	CA 2005-2551948	20050107
EP 1706400	A1	20061004	EP 2005-700746	20050107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1906188	A	20070131	CN 2005-80001977	20050107
BR 2005006760	A	20070522	BR 2005-6760	20050107
JP 2007517825	T	20070705	JP 2006-548229	20050107
IN 2006CN02492	A	20070608	IN 2006-CN2492	20060706
MX 2006PA07820	A	20060901	MX 2006-PA7820	20060707
PRAI US 2004-535626P	P	20040109		
WO 2005-EP93	W	20050107		


OS MARPAT 143:172889
 AB Title compds. I [m = 1-5; R1 = alkylsulfonyl, (un)substituted aminosulfonyl, amino, etc. or two vicinal R1 together with the Ph carbon that they are attached to form heterocyclic ring; R2 = H, (un)substituted alkyl or heterocycle; Z = benzyloxy with provisions] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of IGF-1R. Thus, e.g., II was prepared by cyclization of 1-(3-benzyloxy-phenyl)-2-(2-chloro-pyrimidin-4-yl)-3-dimethylamino-propenone (preparation given) with hydrazine monohydrate and subsequent couplings with 4-amino-benzoic acid and pyrrolidine. The efficacy of I as inhibitors of IGF-1R tyrosine kinase activity was demonstrated using a cellular "Capture ELISA" assay and it was revealed that compds. of the invention displayed IC50 values in the range of 5 nM to 1µM. I as inhibitors of IGF-1R should prove useful in the treatment of proliferative disease. Pharmaceutical compns. comprising I are disclosed.

IT 646525-40-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (compound excluded from invention; preparation of pyrazolyl-pyrimidinyl-amine derivs. as IGF-1R inhibitors)

RN 646525-40-8 CAPLUS
 CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-[4-

10/520,567

(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




IT 860629-83-0P 860629-84-1P 860629-85-2P
860629-86-3P 860629-87-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolyl-pyrimidinyl-amine derivs. as IGF-1R inhibitors)


RN 860629-83-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-N-[4-(1-pyrrolidinylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 860629-84-1 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(dimethylamino)methyl]phenyl]-4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 860629-85-2 CAPLUS

CN Piperazine, 1-methyl-4-[4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 860629-86-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 860629-87-4 CAPLUS

CN Benzamide, 4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-N-(2,2,6,6-tetramethyl-4-piperidiny)- (9CI) (CA INDEX NAME)



IT 860629-91-0P


10/520,567

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of pyrazolyl-pyrimidinyl-amine derivs. as IGF-1R inhibitors)

RN 860629-91-0 CAPLUS

CN Benzoic acid, 4-[[4-[3-[3-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]-2-
pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:371230 CAPLUS
 DN 142:430289
 TI Preparation of pyrimidine compounds as mixed lymphocyte reaction (MLR) inhibitors
 IN Tsuruoka, Hiroyuki; Matsuda, Akihisa; Sugano, Yuichi; Tatsuta, Toru
 PA Sankyo Company, Limited, Japan
 SO PCT Int. Appl., 350 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005037801	A1	20050428	WO 2004-JP15955	20041021
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IE, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	JP 2005145956	A	20050609	JP 2004-302344	20041018
PRAI	JP 2003-360967	A	20031021		

OS MARPAT 142:430289

AB Disclosed is a pyrimidine derivative with excellent MLR inhibitory effect or a pharmacol. acceptable salt thereof. Pyrimidine derivs. represented by the general formula (I) or pharmacol. acceptable salts thereof [R1 = lower alkyl; R2 = each (un)substituted aryl or heterocyclyl; A = NH, O; R3 = H, lower alkyl, heterocyclyl, aryl, heterocyclyl, -NHR6 (wherein R6 = lower alkyl, cycloalkyl-lower alkyl, aralkyl, each (un)substituted cycloalkyl, aryl, or heterocyclyl); R4 = H, lower alkyl, lower alkoxy, cycloalkyl-lower alkyl, aralkyl, each (un)substituted aryl or heterocyclyl; provided that R3 = R4 ≠ H; R5 = H, halo, lower alkyl, cycloalkyl, (un)substituted heterocyclyl, NR7R8, OR7 (wherein R7, R8 = H, cycloalkyl, (un)substituted aryl or lower alkyl)] are prepared These compds. exhibit excellent MLR inhibitory effect and are useful as inhibitors of allograft rejection in bone marrow and organ transplant or for the prevention and/or treatment of inflammatory diseases, organ-specific or organ-nonspecific autoimmune diseases, allergic diseases, chronic rheumatism, multiple sclerosis, inflammatory bowel disease, diabetes, glomerulonephritis, primary biliary liver cirrhosis, chronic active hepatitis, pernicious anemia, chronic thyroiditis, atrophic gastritis, myasthenia gravis, psoriasis, Sjogren's syndrome, systemic lupus erythematosus, rhinitis, asthma, or atopic dermatitis. Thus, 0.1 mmol 4-hydrazino-2,6-bis(2-methoxyphenylamino)pyrimidine was dissolved in 1 mL ethanol, treated with 0.1 mmol 4-acetylpyridine, and stirred for 18 h to give 4-[N'-[1-(pyridin-4-yl)ethylidene]hydrazino]-2,6-bis(2-methoxyphenylamino)pyrimidine. N-methyl-4-[1-[[5-phenyl-2-phenylamino-6-[4-(pyridin-4-yl)pyrazol-1-yl]pyrimidin-4-yl]hydrazono]ethyl]benzenesulfonamide (II) inhibited MLR in human peripheral hemolymphocyte offered from two healthy people with IC50 of 1.0 ng/mL.

IT 850757-38-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

10/520,567

(preparation of pyrimidine compds. as mixed lymphocyte reaction (MLR) inhibitors)

RN 850757-38-9 CAPLUS

CN 4(1H)-Pyrimidinone, 2-[(5-fluoro-2-methylphenyl)amino]-6-(5-phenyl-1H-pyrazol-1-yl)-, [1-(4-pyridinyl)ethylidene]hydrazone (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2004:41464 CAPLUS
 DN 140:111424
 TI Preparation of phenyl-[4-(3-phenyl-1H-pyrazol-4-yl)-pyrimidin-2-yl]-amines
 as protein tyrosine kinase inhibitors
 IN Furet, Pascal; Imbach, Patricia; Ramsey, Timothy Michael; Schlapbach,
 Achim; Scholz, Dieter; Caravatti, Giorgio
 PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

Appl.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004005282	A1	20040115	WO 2003-EP7350	20030708
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
	RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2491635	A1	20040115	CA 2003-2491635	20030708
	AU 2003249993	A1	20040123	AU 2003-249993	20030708
	EP 1521749	A1	20050413	EP 2003-762663	20030708
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003012573	A	20050426	BR 2003-12573	20030708
	CN 1668610	A	20050914	CN 2003-816383	20030708
	JP 2006501183	T	20060112	JP 2004-518751	20030708
	US 2006106027	A1	20060518	US 2005-520567	20050824
PRAI	GB 2002-15844	A	20020709		
	WO 2003-EP7350	W	20030708		

OS MARPAT 140:111424

AB The title compds. [I; m = 1-5; R1 = alkylsulfonyl, (un)substituted aminosulfonyl, amino, etc.; R2 = H, (un)substituted alkyl, heterocyclyl; R3 = H, (un)substituted Ph; R31 = H if R3 = (un)substituted Ph or R31 = (un)substituted Ph if R3 = H; with the proviso], useful for treating diseases which respond to an inhibition of a protein tyrosine kinase, were prepared and formulated. Thus, reacting 2-chloro-4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]pyrimidine with 4-(4-methylpiperazin-1-yl)phenylamine afforded I [R1 = 4-(4-methylpiperazin-1-yl); m = 1; R2 = H; R3 = 4-ClC6H4; R31 = H] which showed IC50 of 0.018 μ M, 0.023 μ M, and 0.01 μ M against EGF-R (HER-1), ErbB-2 (HER-2) and VEGF receptor (KDR), resp. The invention relates also to pharmaceutical compns. comprising the compds. I and to the use of such derivs. - alone or in combination with one or more other pharmaceutically active compds. - for the preparation of pharmaceutical compns. for the treatment especially of a proliferative disease, such as a tumor.

IT 646524-77-8P 646525-46-4P 646525-61-3P
 646525-64-6P 646525-68-0P 646525-96-4P
 646525-99-7P 646526-56-9P 646526-58-1P
 646526-60-5P 646526-74-1P 646526-76-3P
 646526-78-5P 646527-11-9P 646527-39-1P
 646527-43-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


10/520,567

(Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of phenyl[4-(3-phenyl-1H-pyrazol-4-yl)pyrimidin-2-yl]amines as protein tyrosine kinase inhibitors)


RN 646524-77-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-46-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-61-3 CAPLUS

CN Benzoic acid, 4-[[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 646525-64-6 CAPLUS

CN Piperazine, 1-[4-[[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 646525-68-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646525-96-4 CAPLUS

CN Benzenesulfonamide, 3-[[4-[3-(4-chloro-3-methoxyphenyl)-1H-pyrazol-4-yl]-2-


10/520,567

pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 646525-99-7 CAPLUS

CN Benzoic acid, 3-[[4-[3-(4-chloro-3-methoxyphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 646526-56-9 CAPLUS

CN Benzoic acid, 4-[[4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 646526-58-1 CAPLUS

CN Piperazine, 1-methyl-4-[4-[[4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-2-


10/520,567

pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 646526-60-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-74-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-76-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-78-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646527-11-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-39-1 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 646527-43-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




IT 646524-80-3P 646524-82-5P 646524-84-7P
 646524-87-0P 646524-90-5P 646524-93-8P
 646524-96-1P 646524-99-4P 646525-03-3P
 646525-05-5P 646525-08-8P 646525-11-3P
 646525-14-6P 646525-17-9P 646525-20-4P
 646525-23-7P 646525-25-9P 646525-28-2P
 646525-31-7P 646525-34-0P 646525-37-3P
 646525-40-8P 646525-43-1P 646525-49-7P
 646525-52-2P 646525-55-5P 646525-58-8P
 646525-72-6P 646525-76-0P 646525-80-6P
 646525-84-0P 646525-88-4P 646525-92-0P
 646525-93-1P 646526-02-5P 646526-05-8P
 646526-26-3P 646526-31-0P 646526-36-5P
 646526-41-2P 646526-44-5P 646526-49-0P
 646526-52-5P 646526-54-7P 646526-62-7P
 646526-64-9P 646526-66-1P 646526-68-3P
 646526-70-7P 646526-72-9P 646526-80-9P
 646526-81-0P 646526-83-2P 646526-85-4P
 646526-87-6P 646526-90-1P 646526-91-2P
 646526-93-4P 646526-95-6P 646526-97-8P
 646526-99-0P 646527-01-7P 646527-03-9P
 646527-05-1P 646527-07-3P 646527-09-5P
 646527-13-1P 646527-15-3P 646527-17-5P
 646527-19-7P 646527-21-1P 646527-23-3P
 646527-25-5P 646527-27-7P 646527-29-9P
 646527-31-3P 646527-33-5P 646527-35-7P
 646527-37-9P 646527-41-5P 646527-45-9P
 646527-47-1P 646527-49-3P 646527-51-7P
 646527-53-9P 646527-55-1P 646527-57-3P
 646527-59-5P 646527-61-9P 646527-63-1P
 646527-65-3P 646527-67-5P 646527-69-7P
 646527-71-1P 646527-73-3P 646527-75-5P
 646527-77-7P 646527-79-9P 646527-81-3P
 646527-83-5P 646527-85-7P 646527-87-9P
 646527-89-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of phenyl[4-(3-phenyl-1H-pyrazol-4-yl)pyrimidin-2-yl]amines as protein tyrosine kinase inhibitors)


RN 646524-80-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646524-82-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646524-84-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 646524-87-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646524-90-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)


10/520,567

morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646524-93-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(diethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646524-96-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646524-99-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methoxyphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-03-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methoxyphenyl)-1H-pyrazol-4-yl]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646525-05-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-ethylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-08-8 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-[3-(4-ethylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-11-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-[3-(4-methoxyphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-14-6 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-[3-(3-methoxyphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-17-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-methoxyphenyl)-1H-pyrazol-4-yl]-N-[4-[2-(4-morpholinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646525-20-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-methoxyphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-23-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-(4-ethylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-25-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-28-2 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(diethylamino)ethoxy]phenyl]-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-31-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-(3-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-34-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]-N-[4-[2-(dimethylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646525-37-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(3,4-dichlorophenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-40-8 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-[4-(phenylmethoxy)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-43-1 CAPLUS

CN Phenol, 4-[4-[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 646525-49-7 CAPLUS

CN 2-Pyrimidinamine, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646525-52-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[3-[(1-methyl-4-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646525-55-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[(1-methyl-4-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646525-58-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[3-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-72-6 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646525-76-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,4-dichlorophenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-80-6 CAPLUS

CN 1,3-Benzenediamine, N'-[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 646525-84-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-ethoxyphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646525-88-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-ethoxyphenyl)-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646525-92-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chloro-3-methoxyphenyl)-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646525-93-1 CAPLUS

CN Benzenesulfonamide, 3-[[4-[3-(4-chloro-3-hydroxyphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 646526-02-5 CAPLUS

CN Benzoic acid, 3-[[4-[3-(4-chloro-3-hydroxyphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 646526-05-8 CAPLUS

CN Ethanone, 1-[3-[[4-[3-(4-chloro-3-methoxyphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-26-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,3-dimethylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-31-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,3-dimethylphenyl)-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-36-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-41-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-chlorophenyl)-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-44-5 CAPLUS

CN 2-Pyrimidinamine, 4-[1-[2-(dimethylamino)ethyl]-5-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-49-0 CAPLUS

CN 2-Pyrimidinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-52-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(2,4-dichlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-54-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2,4-dichlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-62-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-64-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-66-1 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-68-3 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646526-70-7 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-72-9 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-80-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-81-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-83-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-85-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-87-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646526-90-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-91-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-[2-(dimethylamino)ethyl]-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 646526-93-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-95-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)


10/520,567

methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-97-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646526-99-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-01-7 CAPLUS

CN 2-Pyrimidinamine, 4-[1-[2-(dimethylamino)ethyl]-5-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-03-9 CAPLUS

CN 2-Pyrimidinamine, 4-[1-[2-(dimethylamino)ethyl]-3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-05-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-methylphenyl)-1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-07-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1-(1-methyl-4-piperidinyl)-1H-pyrazol-4-yl]-N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-09-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chloro-3-methylphenyl)-1H-pyrazol-4-yl]-N-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646527-13-1 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[1-methyl-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-15-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[1-methyl-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-17-5 CAPLUS

CN 2-Pyrimidinamine, 4-[1-[2-(dimethylamino)ethyl]-3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646527-19-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-21-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[4-(4-methyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-23-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-(4-methyl-1-piperazinyl)phenyl]-4-[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-25-5 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-[3-[4-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-27-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-29-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-31-3 CAPLUS

CN Piperazine, 1-[3-[[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]benzoyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 646527-33-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-35-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-37-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-41-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-45-9 CAPLUS

CN 2-Pyrimidinamine, N-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 646527-47-1 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-49-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[3-[(4-methyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-51-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-[(1-methyl-4-piperidiny)methyl]-1H-pyrazol-4-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646527-53-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-(4-chlorophenyl)-1-[(1-methyl-4-piperidiny)methyl]-1H-pyrazol-4-yl]-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 646527-55-1 CAPLUS

CN 2-Pyrimidinamine, N-[4-(4-ethyl-1-piperazinyl)phenyl]-4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-57-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-methyl-1-piperazinyl)methyl]phenyl]-4-[3-[3-(trifluoromethyl)phenyl]-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-59-5 CAPLUS

CN 1-Piperazineethanol, 4-[[4-[[4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 646527-61-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1-methyl-1H-pyrazol-4-yl]-N-[3-[(1-methyl-4-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-63-1 CAPLUS

CN Benzenesulfonamide, 3-[[4-[3-(3,5-dimethoxyphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 646527-65-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-67-5 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-4-(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 646527-69-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(1H-tetrazol-5-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-71-1 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-4-[1-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-73-3 CAPLUS

CN 2-Pyrimidinamine, N-[4-[(4-ethyl-1-piperazinyl)methyl]phenyl]-4-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 646527-75-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-[(2,2,6,6-tetramethyl-4-piperidyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-77-7 CAPLUS

CN 2-Pyrimidinamine, 4-(3-phenyl-1H-pyrazol-4-yl)-N-[4-[(2,2,6,6-tetramethyl-4-piperidyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 646527-79-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(4-ethyl-1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)




RN 646527-81-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 646527-83-5 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[3-[(1-methyl-4-piperidinyloxy)methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 646527-85-7 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[3-[(1-methyl-4-piperidinyloxy)methoxy]phenyl]- (9CI) (CA INDEX NAME)

10/520,567




RN 646527-87-9 CAPLUS

CN 2-Pyrimidinamine, 4-[1-methyl-3-(4-methylphenyl)-1H-pyrazol-4-yl]-N-[3-[(1-methyl-4-piperidinyl)methoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 646527-89-1 CAPLUS

CN Benzenesulfonamide, 4-[[4-[3-(4-methylphenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 646528-47-4


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of phenyl[4-(3-phenyl-1H-pyrazol-4-yl)pyrimidin-2-yl]amines as

10/520,567

protein tyrosine kinase inhibitors)

RN 646528-47-4 CAPLUS

CN Benzonitrile, 4-[[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:590836 CAPLUS
 DN 139:149624
 TI Preparation of 1,4-diarylpirazole inhibitors of src and other protein
 kinases
 IN Young, Choon Moon
 PA Vertex Pharmaceuticals Incorporated, USA
 SO U.S. Pat. Appl. Publ., 35 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003144309	A1	20030731	US 2002-146984	20020516
	US 6884804	B2	20050426		
PRAI	US 2002-146984		20020516		

OS MARPAT 139:149624

AB Title compds. I [G = XR, XAr; X = alkylidene wherein one or two
 non-adjacent methylene units of X are replaced by O, amino, S, CO, etc.; A
 = N, CR; R = H, aliphatic, etc.; Ar = (un)substituted 5-6 membered

(un)saturated

monocyclic ring, etc.; R1 = TnR, TnAr; n = 0-1; T = CO, CO2, COCO, etc.;
 R2 = H, Ar, aliphatic; R3 = R, Ar] are prepared For instance,
 3-(bis(methylsulfanyl)methylene)pentane-2,4-dione (preparation given) is
 condensed with (pyridin-2-yl)hydrazine to give 1-[5-methyl-3-
 (methylsulfanyl)-1-(pyridin-2-yl)-1H-pyrazole-4-yl]ethanone. This
 intermediate is reacted with DMFDMA (reflux) and the resulting
 β -amino enone condensed with N-(3-benzyloxyphenyl)guanidine to give
 II. Many of the compds. have $K_i \leq 1 \mu\text{M}$ for src kinase. I are
 inhibitors of protein kinase, particularly inhibitors of src mammalian
 protein kinase involved in cell proliferation, cell death in response to
 extracellular stimuli.

IT 475573-43-4P 475573-44-5P 475573-45-6P
 475573-46-7P 475573-47-8P 475573-48-9P
 475573-49-0P 475573-50-3P 475573-51-4P
 475573-52-5P 475573-53-6P 475573-54-7P
 475573-55-8P 475573-56-9P 475573-57-0P
 475573-58-1P 475573-59-2P 475573-60-5P
 475573-61-6P 475573-62-7P 475573-63-8P
 475573-64-9P 475573-65-0P 475573-66-1P
 475573-67-2P 475573-68-3P 475573-69-4P
 475573-70-7P 475573-71-8P 475573-72-9P
 475573-73-0P 475573-74-1P 475573-75-2P
 475573-76-3P 475573-77-4P 475573-78-5P
 475573-79-6P 475573-80-9P 475573-81-0P
 475573-82-1P 475573-83-2P 475573-84-3P
 475573-85-4P 475573-86-5P 475573-87-6P
 475573-88-7P 475573-89-8P 475573-90-1P
 475573-91-2P 475573-92-3P 475573-93-4P
 475573-94-5P 475573-95-6P 475573-96-7P
 475573-97-8P 475573-98-9P 475573-99-0P
 475574-00-6P 475574-01-7P 475574-02-8P
 475574-03-9P 475574-04-0P 475574-05-1P
 475574-06-2P 475574-07-3P 475574-08-4P
 475574-09-5P 475574-10-8P 475574-11-9P
 475574-12-0P 475574-13-1P 475574-15-3P
 475574-16-4P 475574-17-5P 475574-18-6P
 475574-19-7P 475574-20-0P 475574-21-1P
 475574-22-2P 475574-23-3P 475574-24-4P


475574-25-5P 475574-26-6P 475574-27-7P
 475574-28-8P 475574-29-9P 475574-30-2P
 475574-31-3P 475574-32-4P 475574-33-5P
 475574-34-6P 475574-35-7P 475574-36-8P
 475574-37-9P 475574-39-1P 475574-40-4P
 475574-41-5P 475574-42-6P 475574-43-7P
 475574-44-8P 475574-45-9P 475574-46-0P
 475574-47-1P 475574-48-2P 475574-49-3P
 475574-50-6P 475574-56-2P 475574-57-3P
 475574-58-4P 475574-59-5P 475574-60-8P
 475574-87-9P 475574-88-0P 475574-89-1P
 475574-90-4P 475574-91-5P 475574-92-6P
 475574-93-7P 475574-94-8P 475574-95-9P
 475575-07-6P 475575-08-7P 475575-09-8P
 475575-10-1P 475575-11-2P 475575-12-3P
 475575-13-4P 475575-14-5P 475575-15-6P
 475575-16-7P 475575-17-8P 475575-18-9P
 475575-19-0P 475575-20-3P 475575-21-4P
 475575-22-5P 475575-24-7P 475575-25-8P
 475575-26-9P 475575-27-0P 475575-28-1P
 475575-29-2P 475575-30-5P 571207-40-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of 1-phenyl-4-pyrimidinyl-substituted pyrazole inhibitors of
 src and other protein kinases)


RN 475573-43-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-
 phenyl- (9CI) (CA INDEX NAME)




RN 475573-44-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-
 1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-45-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-46-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475573-47-8 CAPLUS

CN Benzamide, 3-methyl-4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-48-9 CAPLUS

CN Benzonitrile, 3-methyl-4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-49-0 CAPLUS

CN Benzonitrile, 3-[[4-[[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-50-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-51-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-52-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-53-6 CAPLUS

CN Benzonitrile, 3-[[4-[5-ethyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-54-7 CAPLUS

CN Benzoic acid, 3-[[4-[5-ethyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-55-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-56-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-57-0 CAPLUS


CN Ethanone, 1-[4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475573-58-1 CAPLUS
 CN Methanone, 4-[[4-[[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)



RN 475573-59-2 CAPLUS
 CN Benzamide, 4-[[4-[[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-60-5 CAPLUS
 CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-61-6 CAPLUS

CN Benzonitrile, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-62-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-ethenylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-63-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-64-9 CAPLUS

CN Benzonitrile, 2-methyl-4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-65-0 CAPLUS

CN Ethanone, 1-[3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475573-66-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-ethyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-68-3 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-69-4 CAPLUS

CN 2-Pyrimidinamine, N-[1,1'-biphenyl]-4-yl-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-70-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-71-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-72-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-73-0 CAPLUS

CN Benzonitrile, 4-methoxy-3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-74-1 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 475573-75-2 CAPLUS

CN Benzonitrile, 4-fluoro-3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-76-3 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-77-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-78-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-79-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-80-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-81-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-82-1 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 475573-83-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 475573-84-3 CAPLUS

CN 2-Pyrimidinamine, N-(2-ethenylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-85-4 CAPLUS

CN 2-Pyrimidinamine, N-(2-chloro-5-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-86-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-87-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-88-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,5-dimethoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-89-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-90-1 CAPLUS

CN Benzonitrile, 3-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-91-2 CAPLUS

CN Benzonitrile, 4-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-92-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 475573-93-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 475573-94-5 CAPLUS

CN Benzonitrile, 4-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 475573-95-6 CAPLUS

CN Benzonitrile, 4-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 475573-96-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-97-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(1-methylethyl)thio]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-98-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(2-methylpropyl)thio]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-99-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-00-6 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-01-7 CAPLUS


CN 2-Pyrimidinamine, 4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



Me-(CH₂)₄-S

RN 475574-02-8 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(hexylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



Me-(CH₂)₅-S


RN 475574-03-9 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(heptylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)

Me-(CH₂)₆-S


RN 475574-04-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(octylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)

Me-(CH₂)₇-S


RN 475574-05-1 CAPLUS

CN Acetonitrile, [[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]- (9CI) (CA INDEX NAME)

NC-CH₂-S


RN 475574-06-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(2-methoxyethyl)thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-07-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(3,3,3-trifluoropropyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-08-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(cyclopropylmethyl)thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-09-5 CAPLUS

CN 2-Propanone, 1-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]- (9CI) (CA INDEX NAME)




RN 475574-10-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[[2-(dimethylamino)ethyl]thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-11-9 CAPLUS

CN Acetamide, N-[2-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]ethyl]- (9CI) (CA INDEX NAME)




RN 475574-12-0 CAPLUS

CN Carbamic acid, [2-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]ethyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 475574-13-1 CAPLUS

CN Ethanol, 2-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 475574-15-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-butynylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-16-4 CAPLUS

CN Ethanone, 1-[4-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475574-17-5 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-18-6 CAPLUS

CN Benzonitrile, 4-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-19-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-20-0 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-21-1 CAPLUS

CN Benzonitrile, 2-fluoro-5-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-22-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-23-3 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 475574-24-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 475574-25-5 CAPLUS

CN Acetamide, N-[3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475574-26-6 CAPLUS

CN 1,3-Benzenediamine, N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 475574-27-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475574-28-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475574-29-9 CAPLUS

CN Benzonitrile, 4-[[4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 475574-30-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 475574-31-3 CAPLUS

CN Benzonitrile, 4-[[4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-32-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475574-33-5 CAPLUS

CN Benzonitrile, 3-[[4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-34-6 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-35-7 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-36-8 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-[(2-methylpropyl)thio]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-37-9 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-[(2-methylpropyl)thio]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-39-1 CAPLUS

CN Benzonitrile, 4-[[4-[3-(2-butynylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 475574-40-4 CAPLUS

CN Benzonitrile, 3-[[4-[3-(2-butynylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-41-5 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 475574-42-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-43-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-44-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 475574-45-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-46-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-47-1 CAPLUS

CN Phenol, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-48-2 CAPLUS

CN Benzenepropanoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 475574-49-3 CAPLUS


CN Benzeneacetic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 475574-50-6 CAPLUS


CN D-Valine, N-[3-[3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475574-56-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-57-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 475574-58-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-59-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-60-8 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 475574-87-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(phenylthio)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-88-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(phenylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-89-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(1-phenylethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-90-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(2-pyridinylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-91-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(1,3-dioxan-2-ylmethyl)thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-92-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(2-thienylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-93-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(1-methyl-4-piperidinyl)thio]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(3-pyridinylthio)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(2-thiazolylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-07-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(propylamino)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-08-7 CAPLUS

CN Benzonitrile, 3-[[4-[3-(butylamino)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475575-09-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(2-methylpropyl)amino]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-10-1 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 475575-11-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylamino)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-12-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(phenylmethyl)amino]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-13-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(1-methyl-4-piperidinyl)amino]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-14-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-methyl-1-phenyl-3-(1-piperidinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-15-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-methyl-3-(4-morpholinyl)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-16-7 CAPLUS

CN 3-Piperidinol, 1-[4-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 475575-17-8 CAPLUS

CN 4-Piperidinol, 1-[4-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




```
RN      475575-18-9  CAPLUS
CN      Ethanol, 2-[[4-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-
        phenyl-1H-pyrazol-3-yl]amino]- (9CI)  (CA INDEX NAME)
```




```

RN      475575-19-0  CAPLUS
CN      1H-Indole-3-ethanamine, N-[5-methyl-1-phenyl-4-[2-(phenylamino)-4-
pyrimidinyl]-1H-pyrazol-3-yl]- (9CI)  (CA INDEX NAME)

```




RN	475575-20-3	CAPLUS
CN	2-Pyrimidinamine, 4-[3-[2-(dimethylamino)ethoxy]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)	




RN 475575-21-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(2-methylpropoxy)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-22-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylmethoxy)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylsulfonyl)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-25-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methanesulfonyl)-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475575-26-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylsulfonyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-27-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-3-[(4-methylphenyl)sulfonyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-28-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-3-(2-naphthalenylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 475575-29-2 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(butylsulfinyl)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-30-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylsulfinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)


10/520,567



RN 571207-40-4 CAPLUS

CN L-Cysteine, S-[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:472310 CAPLUS
 DN 139:32090
 TI Preparation of pyrazolylpyrimidine derivative fungicides
 IN Mueller, Urs; Eberle, Martin; Pillonel, Christian
 PA Syngenta Participations Ag, Switz.
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2

DT Patent
 LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003049542	A1	20030619	WO 2002-IB5146	20021205
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2460122	A1	20030619	CA 2002-2460122	20021205
	AU 2002351124	A1	20030623	AU 2002-351124	20021205
	EP 1455579	A1	20040915	EP 2002-785837	20021205
	EP 1455579	B1	20060906		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	BR 2002013140	A	20041019	BR 2002-13140	20021205
	AT 338461	T	20060915	AT 2002-785837	20021205
	US 2005080101	A1	20050414	US 2004-497975	20040603
PRAI	GB 2001-29476	A	20011210		
	WO 2002-IB5146	W	20021205		
OS	MARPAT 139:32090				
AB	The pyrazolylpyrimidine derivs. I [R1 = H, alkyl, alkenyl, alkynyl or XR8; X = CO, CO2, CONR9, SO, SO2 or SO2NR10; R2 = H, NH2 or NHCOR11; R3 = (un)substituted Ph or thenyl; R4 = H, NO2, CN, etc.; R5 = H, alkyl, alkoxy, OH or halo; R6, R7 = H, alkyl, alkoxy, halo; R8, R11 = (halo)alkyl, (halo)cycloalkyl, cycloalkylalkyl, etc.; R9, R10 = (halo)alkyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl] are prepared as fungicides.				
IT	541507-64-6P 541507-67-9P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate in preparation of pyrazolylpyrimidine derivative fungicide)				
RN	541507-64-6 CAPLUS				
CN	Benzoic acid, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)				



RN 541507-67-9 CAPLUS

CN Benzenemethanol, 3-[[4-[[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




IT 541507-56-6P 541507-63-5P 541507-66-8P
 541507-68-0P 541507-69-1P 541507-70-4P
 541507-71-5P 541507-73-7P 541507-74-8P
 541507-75-9P 541507-76-0P 541507-77-1P
 541507-78-2P 541507-79-3P 541507-80-6P
 541507-81-7P 541507-82-8P 541507-83-9P
 541507-84-0P 541507-85-1P 541507-86-2P
 541507-88-4P 541507-89-5P 541507-90-8P
 541507-92-0P 541507-93-1P 541507-95-3P
 541507-96-4P 541507-97-5P 541507-98-6P
 541507-99-7P 541508-00-3P 541508-01-4P
 541508-02-5P 541508-03-6P 541508-04-7P
 541508-05-8P 541508-07-0P 541508-09-2P
 541508-11-6P 541508-13-8P 541508-15-0P
 541508-17-2P 541508-19-4P

RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation as fungicide)


RN 541507-56-6 CAPLUS

CN 2-Pyrimidinamine, 4-(3-amino-5-phenyl-1H-pyrazol-4-yl)-N-phenyl- (9CI)
 (CA INDEX NAME)




RN 541507-63-5 CAPLUS

CN Benzenemethanol, 3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 541507-66-8 CAPLUS

CN 1H-Pyrazole, 1-acetyl-4-[2-[[3-[(acetyloxy)methyl]phenyl]amino]-4-pyrimidinyl]-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 541507-68-0 CAPLUS

CN Benzenemethanol, α-methyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-, acetate (ester) (9CI) (CA INDEX NAME)




RN 541507-69-1 CAPLUS

CN 1H-Pyrazole, 1-acetyl-4-[2-[[3-[1-(acetyloxy)ethyl]phenyl]amino]-4-pyrimidinyl]-3-phenyl- (9CI) (CA INDEX NAME)




RN 541507-70-4 CAPLUS

CN Carbonic acid, 3-[[4-(1-acetyl-3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]phenyl methyl ester (9CI) (CA INDEX NAME)




RN 541507-71-5 CAPLUS

CN Sulfamic acid, dimethyl-, 3-[[4-(1-acetyl-3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]phenyl ester (9CI) (CA INDEX NAME)




RN 541507-73-7 CAPLUS

CN Carbonic acid, 3-[[4-(1-acetyl-3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]phenyl ethyl ester (9CI) (CA INDEX NAME)




RN 541507-74-8 CAPLUS

CN 2-Pyrimidinamine, N-phenyl-4-(3-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)




RN 541507-75-9 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 541507-76-0 CAPLUS
 CN Benzonitrile, 3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI)
 (CA INDEX NAME)



RN 541507-77-1 CAPLUS
 CN Phenol, 3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA
 INDEX NAME)




RN 541507-78-2 CAPLUS
 CN 1H-Pyrazole-1-acetonitrile, 4-[2-[(3-hydroxyphenyl)amino]-4-pyrimidinyl]-3-
 phenyl- (9CI) (CA INDEX NAME)




RN 541507-79-3 CAPLUS

CN Benzeneacetonitrile, 3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-
 (9CI) (CA INDEX NAME)




RN 541507-80-6 CAPLUS

CN Benzoic acid, 3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-,
methyl ester (9CI) (CA INDEX NAME)




RN 541507-81-7 CAPLUS

CN Benzoic acid, 3-[[4-[1-[(dimethylamino)sulfonyl]-3-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 541507-82-8 CAPLUS

CN Benzenemethanol, 3-[[4-[3-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX .NAME)




RN 541507-83-9 CAPLUS

CN 1H-Pyrazole, 3-(4-chlorophenyl)-4-[2-[[3-(1-hydroxyethyl)phenyl]amino]-4-pyrimidinyl]-1-(1-oxopropyl)- (9CI) (CA INDEX NAME)




RN 541507-84-0 CAPLUS

CN 1H-Pyrazole-1-sulfonamide, 3-(4-chlorophenyl)-4-[2-[[3-(1-hydroxyethyl)phenyl]amino]-4-pyrimidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 541507-85-1 CAPLUS

CN 1H-Pyrazole-1-carboxylic acid, 3-(4-chlorophenyl)-4-[2-[[3-(1-hydroxyethyl)phenyl]amino]-4-pyrimidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 541507-86-2 CAPLUS

CN Benzenemethanol, 3-[[4-[3-amino-5-(4-chlorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-α-methyl- (9CI) (CA INDEX NAME)




RN 541507-88-4 CAPLUS

CN 1H-Pyrazole, 3-(4-chlorophenyl)-4-[2-[[3-(1-hydroxyethyl)phenyl]amino]-4-pyrimidinyl]-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 541507-89-5 CAPLUS

CN Benzoic acid, 3-[[4-[1-[(dimethylamino)carbonyl]-3-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 541507-90-8 CAPLUS


CN Ethanone, 1-[3-[[4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 541507-92-0 CAPLUS


CN Benzenemethanol, α -methyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)

RN 541507-93-1 CAPLUS

CN Benzenemethanol, α,α -dimethyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)


RN 541507-95-3 CAPLUS

CN Benzenemethanol, α -ethyl- α -methyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 541507-96-4 CAPLUS

CN Benzenemethanol, α -methyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- α -2-propenyl- (9CI) (CA INDEX NAME)




RN 541507-97-5 CAPLUS

CN Benzamide, N-methyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 541507-98-6 CAPLUS

CN Benzamide, N,N-dimethyl-3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 541507-99-7 CAPLUS

CN Ethanone, 1-[3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]phenyl]-, O-methyloxime (9CI) (CA INDEX NAME)




RN 541508-00-3 CAPLUS

CN Ethanone, 1-[3-[[4-(3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]phenyl]-, oxime (9CI) (CA INDEX NAME)




RN 541508-01-4 CAPLUS

CN 2-Pyrimidinamine, 4-(3-phenyl-1H-pyrazol-4-yl)-N-[3-(2-propynyloxy)phenyl]- (9CI) (CA INDEX NAME)




RN 541508-02-5 CAPLUS

CN 2-Pyrimidinamine, N-[3-(ethoxymethoxy)phenyl]-4-(3-phenyl-1H-pyrazol-4-yl)-
(9CI) (CA INDEX NAME)




RN 541508-03-6 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-3-phenyl-1H-pyrazol-4-yl)-N-(3-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 541508-04-7 CAPLUS

CN 2-Pyrimidinamine, N-[3-(ethoxymethoxy)phenyl]-4-[3-phenyl-1-(2-propynyl)-
1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 541508-05-8 CAPLUS

CN 2-Pyrimidinamine, 4-(1-butyl-3-phenyl-1H-pyrazol-4-yl)-N-[3-(ethoxymethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 541508-07-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-3-phenyl-1H-pyrazol-4-yl)-N-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 541508-09-2 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-3-phenyl-1H-pyrazol-4-yl)-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 541508-11-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-amino-3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 541508-13-8 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-3-phenyl-1H-pyrazol-4-yl)-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 541508-15-0 CAPLUS

CN 2-Pyrimidinamine, 4-(5-amino-3-phenyl-1H-pyrazol-4-yl)-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 541508-17-2 CAPLUS

CN Phenol, 3-[[4-(1-butyl-3-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]-
(9CI) (CA INDEX NAME)



RN 541508-19-4 CAPLUS

CN 1H-Pyrazole-1-carboxamide, 4-[2-[(3-acetylphenyl)amino]-4-pyrimidinyl]-N,N-
dimethyl-3-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:150531 CAPLUS

DN 138:187765

TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors

IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew
 J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi

PA G.D. Searle and Co., USA

SO U.S., 415 pp., Cont.-in-part of U.S. Ser. No. 196,623.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6525059	B1	20030225	US 2000-513351	20000224
	US 6514977	B1	20030204	US 1998-196623	19981120
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2003200580	A1	20030501	AU 2003-200580	20030217
	US 7071198	B2	20060704	US 2004-840734	20040505
	US 2007078146	A1	20070405		
PRAI	US 1998-196623	A2	19981120		
	WO 1999-US26007	A1	19991117		
	US 1997-47570P	P	19970522		
	AU 1998-75883	A3	19980522		
	US 1998-83670	A2	19980522		
	US 2000-513351	A3	20000224		
	US 2001-21780	A3	20011207		

OS MARPAT 138:187765

AB Title compds. [I; R1 = H, OH, NH₂, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R₃CH₂COMe (R₃ = 4-pyridinyl) was condensed with 3,4-F(MeO)C₆H₃CHO to give the butenone (80%), which was cyclocondensed with TsNHNH₂ to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC₅₀ of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC₅₀ of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.

IT 271574-63-1P 271574-64-2P


RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase

*Same
as #17*

inhibitors by cyclocondensation of hydrazines with ketones)


RN 271574-63-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:117807 CAPLUS
 DN 138:153548
 TI Preparation of 4-(pyrazolyl)-2-pyrimidinamines as tyrosine kinase inhibitors
 IN Fraley, Mark E.; Peckham, Jennifer P.; Arrington, Kenneth L.; Hoffman, William F.; Hartman, George D.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 96 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003011837	A1	20030213	WO 2002-US23879	20020726
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002355733	A1	20030217	AU 2002-355733	20020726
	US 2004235875	A1	20041125	US 2004-485296	20040129
	US 7109204	B2	20060919		
PRAI	US 2001-309399P	P	20010801		
	WO 2002-US23879	W	20020726		

OS MARPAT 138:153548

AB The present invention relates to title compds. I [wherein R1a = H, (un)substituted alkyl, OR8, or N(R8)2; R1 and R2 = independently H, halo, CF3, (CH2)tR9COR8, COR9, (CH2)tOR8, CN, (CH2)tNR7R8, (CH2)tCONR7R8, CO2R8, (CH2)tSOO-2(CH2)tNR7R8, or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, alkenyl, or alkynyl; R3 = independently H, CN, halo, N(R3)2, (CH2)tOR8, or (un)substituted (ar)alkyl or aryl; R7 = independently H or (un)substituted (ar)alkyl; R8 = independently H or (un)substituted (cyclo)alkyl, aryl, heterocyclyl, or aralkyl; or NR7R8 = (un)substituted heterocyclyl; R9 = independently (un)substituted heterocyclyl, alkyl, or aryl; V = a bond, aryl, or heterocyclyl; W = aryl or heterocyclyl; m = 0-2; n = 0-6; p = 0-4; t = independently 0-6; and pharmaceutically acceptable salts, hydrates, and stereoisomers thereof], which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compns. which contain these compds., and methods of using them to treat tyrosine kinase-dependent diseases and conditions. For example, 2-(methylthio)pyrimidine-4-carboxylic acid was amidated with dimethylhydroxylamine•HCl in the presence of EDC and TEA, and the product treated with MeMgBr in Et2O to give 1-[2-(methylthio)pyrimidin-4-yl]ethanone. Coupling with N,N-dimethylformamide dimethylacetal followed by cyclization with phenylhydrazine afforded 2-(methylthio)-4-(1-phenyl-1H-pyrazol-3/5-yl)pyrimidine. Oxidation with oxone and reaction with 3-chloroaniline provided the 4-(pyrazolyl)-2-pyrimidinamine II. In bioassays, I inhibited VEGF-stimulated mitogenesis of human vascular endothelial cells in culture with IC50 values between 0.01 µM and 5.0 µM. Thus, I are useful for the treatment of angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals (no data).

IT 496863-54-8P, Methyl 4-[[4-(1-phenyl-1H-pyrazol-5-yl)pyrimidin-2-


yl]amino]benzoate 496863-55-9P, 4-[[4-(1-Phenyl-1H-pyrazol-5-yl)pyrimidin-2-yl]amino]benzoic acid

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(tyrosine kinase inhibitor; preparation of (pyrazolyl)pyrimidinamine tyrosine kinase inhibitors by reacting amines with (methylsulfonyl)(pyrazolyl)pyrimidines)

RN 496863-54-8 CAPLUS


CN Benzoic acid, 4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



2 D 48

RN 496863-55-9 CAPLUS

CN Benzoic acid, 4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



IT 496863-53-7P, N-(3-Chlorophenyl)-4-(1-phenyl-1H-pyrazol-5-yl)pyrimidin-2-amine 496863-56-0P, N-[4-[(4-Methylpiperazin-1-yl)carbonyl]phenyl]-4-(1-phenyl-1H-pyrazol-5-yl)pyrimidin-2-amine 496863-57-1P, N-[4-[(4-Methylpiperazin-1-yl)carbonyl]phenyl]-4-(1-phenyl-1H-pyrazol-5-yl)pyrimidin-2-amine trifluoroacetate 496863-63-9P, N-(3,5-Dimethylphenyl)-4-(4-phenyl-1H-pyrazol-5-yl)pyrimidin-2-amine 496863-69-5P, N-(3,5-Dimethylphenyl)-4-(1-phenyl-1H-pyrazol-5-yl)pyrimidin-2-amine 496863-70-8P, 4-[1-(4-Chlorophenyl)-1H-pyrazol-5-yl]-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496863-71-9P, 4-[1-(3-Chlorophenyl)-1H-pyrazol-5-yl]-N-(3,5-dimethylphenyl)pyrimidin-2-amine 496863-72-0P, N-(3,5-Dimethylphenyl)-4-(1-phenyl-1H-pyrazol-3-yl)pyrimidin-2-amine 496863-73-1P, N-(3,5-Dimethylphenyl)-4-[1-(3,4-dimethylphenyl)-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-75-3P, N-(3,5-Dimethylphenyl)-4-[1-[3-(trifluoromethyl)phenyl]-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-76-4P, N-(3,5-Dimethylphenyl)-4-[1-(3-ethynylphenyl)-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-77-5P, N-(3,5-Dimethylphenyl)-4-[1-(3,5-dimethylphenyl)-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-78-6P, N-(3,5-Dimethylphenyl)-4-[1-(4-methoxyphenyl)-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-80-0P, N-(3,5-Dimethylphenyl)-4-[1-(3-methoxyphenyl)-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-82-2P, N-(3,5-Dimethylphenyl)-4-[1-(3-fluorophenyl)-1H-pyrazol-5-yl]pyrimidin-2-amine 496863-84-4P, 4-(1-Phenyl-1H-pyrazol-5-yl)-N-[4-(piperazin-1-yl)phenyl]pyrimidin-2-amine RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


10/520,567

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(tyrosine kinase inhibitor; preparation of (pyrazolyl)pyrimidinamine tyrosine kinase inhibitors by reacting amines with (methylsulfonyl) (pyrazolyl)pyrimidines)


RN 496863-53-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(1-phenyl-1H-pyrazol-5-yl)- (9CI) (CA INDEX NAME)



RN 496863-56-0 CAPLUS

CN Piperazine, 1-methyl-4-[4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]benzoyl]- (9CI) (CA INDEX NAME)




RN 496863-57-1 CAPLUS

CN Piperazine, 1-methyl-4-[4-[[4-(1-phenyl-1H-pyrazol-5-yl)-2-pyrimidinyl]amino]benzoyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 496863-56-0


CMF C25 H25 N7 O



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 496863-63-9 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(4-phenyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




RN 496863-69-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(1-phenyl-1H-pyrazol-5-yl)-
(9CI) (CA INDEX NAME)




RN 496863-70-8 CAPLUS

CN 2-Pyrimidinamine, 4-[1-(4-chlorophenyl)-1H-pyrazol-5-yl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496863-71-9 CAPLUS

CN 2-Pyrimidinamine, 4-[1-(3-chlorophenyl)-1H-pyrazol-5-yl]-N-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 496863-72-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-(1-phenyl-1H-pyrazol-3-yl)-
(9CI) (CA INDEX NAME)




RN 496863-73-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-(3,4-dimethylphenyl)-1H-
pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 496863-75-3 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-[3-(trifluoromethyl)phenyl]-
1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 496863-76-4 CAPLUS


CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-(3-ethynylphenyl)-1H-pyrazol-
5-yl]- (9CI) (CA INDEX NAME)

5-yl]- (9CI) (CA INDEX NAME)




RN 496863-77-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-(3,5-dimethylphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 496863-78-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-(4-methoxyphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 496863-80-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-(3-methoxyphenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)




RN 496863-82-2 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[1-(3-fluorophenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 496863-84-4 CAPLUS

CN 2-Pyrimidinamine, 4-(1-phenyl-1H-pyrazol-5-yl)-N-[4-(1-piperazinyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2003:92403 CAPLUS
 DN 138:137307
 TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
 IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce
 Zuowu; Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew
 J.; Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Koszyk, Francis J.; Liao, Shuyuan; Metz, Suzanne;
 Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.; Selness, Shaun
 Raj; South, Michael S.; Stealey, Michael A.; Talley, John Jeffrey;
 Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Khanna, Ish K.; Yu,
 Yi
 PA G.D. Searle and Co., USA
 SO U.S., 541 pp., Cont.-in-part of U.S. Ser. No. 83,670.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 5

Same as #17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6514977	B1	20030204	US 1998-196623	19981120
	CA 2351725	A1	20000602	CA 1999-2351725	19991117
	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	EP 1144403	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200102001	T2	20011221	TR 2001-200102001	19991117
	BR 9915420	A	20020122	BR 1999-15420	19991117
	HU 200200130	A2	20020629	HU 2002-130	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	NZ 512344	A	20031128	NZ 1999-512344	19991117
	AU 774262	B2	20040624	AU 2000-21454	19991117
	AT 278685	T	20041015	AT 1999-965756	19991117
	EP 1500657	A1	20050126	EP 2004-23186	19991117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	PT 1144403	T	20050131	PT 1999-965756	19991117
	ES 2229809	T3	20050416	ES 1999-965756	19991117
	US 6525059	B1	20030225	US 2000-513351	20000224
	ZA 2001003882	A	20021014	ZA 2001-3882	20010514
	MX 2001PA05043	A	20010710	MX 2001-PA5043	20010518
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
	US 6423713	B1	20020723	US 2001-918481	20010731
	HK 1040705	A1	20050304	HK 2002-102213	20020322
	US 6617324	B1	20030909	US 2002-114297	20020402
	AU 2003200580	A1	20030501	AU 2003-200580	20030217
	US 2004176433	A1	20040909	US 2003-374781	20030225
	US 7153959	B2	20061226		
	US 7071198	B2	20060704	US 2004-840734	20040505
	US 2007078146	A1	20070405		

PRAI US 1997-47570P P 19970522
 US 1998-83670 A2 19980522
 AU 1998-75883 A3 19980522
 US 1998-196623 A 19981120
 EP 1999-965756 A3 19991117
 WO 1999-US26007 W 19991117
 US 2000-513351 A3 20000224
 US 2001-918481 A3 20010731
 US 2001-21780 A3 20011207
 US 2002-114297 A3 20020402

OS MARPAT 138:137307


AB Title compds. [I; R1 = H, OH, NH₂, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = (un)substituted piperidinyl or piperazinyl; R3 = (un)substituted pyrimidinyl; R4 = (un)substituted Ph; and pharmaceutically acceptable salts or tautomers thereof] were prepared by solution phase and solid phase parallel array reactions of ketones with hydrazines. Thus, R₃CH₂COMe (R₃ = 4-pyridinyl) was condensed with 3,4-F(MeO)C₆H₃CHO to give the butenone (80%), which was cyclocondensed with TsNHNH₂ to afford the title compound II (20.7%). The latter inhibited human p38 kinase activity in vitro with IC₅₀ of 4.6 μM and inhibited tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) release from human peripheral blood mononuclear cells following stimulation with lipopolysaccharide with IC₅₀ of 0.5 μM. Thus, I are useful for the treatment of inflammation, arthritis, asthma, and other disorders mediated by p38 kinase and TNFα.

IT 271574-63-1P 271574-64-2P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)

RN 271574-63-1 CAPLUS


CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

10/520,567



RE.CNT 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:888716 CAPLUS
 DN 137:384853
 TI Preparation of pyrazolyl pyridinamines and pyrimidinamines as inhibitors
 of Src and other protein kinases
 IN Moon, Young-Choon
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 75 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002092573	A2	20021121	WO 2002-US15606	20020516
	WO 2002092573	A3	20040122		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2446864	A1	20021121	CA 2002-2446864	20020516
	AU 2002308748	A1	20021125	AU 2002-308748	20020516
	EP 1404669	A2	20040407	EP 2002-769762	20020516
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004534754	T	20041118	JP 2002-589459	20020516
PRAI	WO 2002-US15606	W	20020516		
OS	MARPAT 137:384853				

AB Title compds. I [wherein G = XR or XAr; X = independently alkylidene wherein 1-2 non-adjacent methylene units are independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO₂, NRSO₂, SO₂NR, or NRSO₂NR; A = N or CR; R = H or (un)substituted aliphatic group; or NR₂ = heterocyclyl; Ar = (un)substituted 5-6 membered monocyclic ring with 0-3 heteroatoms or 8-10 membered bicyclic ring with 0-4 heteroatoms; R₁ = TnR or TnAr; n = 0-1; T = CO, CO₂, COCO, COCH₂CO, CONR, SO₂, or SO₂NR; R₂ = H, Ar, or (un)substituted aliphatic group; R₃ = R or Ar; or pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of protein kinase, particularly inhibitors of Src mammalian protein kinase involved in cell proliferation, cell death and response to extracellular stimuli (no data). For example, 3-dimethylamino-1-[5-methyl-3-methylsulfanyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]propanone was coupled with N-(3-benzyloxyphenyl)guanidine in MeOH to give II (40%). I and compns. containing I are useful in the treatment and prevention of various inflammatory, autoimmune, destructive bone, proliferative, infectious, neurodegenerative, allergic, and cardiac disorders and diseases (no data).

IT 475573-43-4P, N-Phenyl-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-44-5P, N-(4-Methoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-45-6P, N-(3,4-Dimethoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-46-7P, N-(2-Methylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-47-8P, N-(2-Methyl-4-(aminocarbonyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-48-9P,

N-(2-Methyl-4-cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-49-0P,
 N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-50-3P, N-(2-Methyl-3-fluorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-51-4P, N-(2-Methyl-4-fluorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-52-5P, N-(2-(Trifluoromethyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-53-6P, N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-54-7P, N-(3-Carboxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-55-8P, N-(3-Fluorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-56-9P, N-(4-Fluorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-57-0P, N-(4-Acetylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-58-1P, N-(4-Benzoylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-59-2P, N-(4-(Aminocarbonyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-60-5P, N-(3,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-61-6P, N-(4-Cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-62-7P, N-(3-Vinylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-63-8P, N-(3-(Methylthio)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-64-9P, N-(3-Methyl-4-cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-65-0P, N-(3-Acetylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-66-1P, N-Phenyl-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-67-2P, N-(2-Methoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-68-3P, N-(3-Carboxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-69-4P, N-(4-Phenylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-70-7P, N-(3,5-Dimethylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-71-8P, N-(4-(Methylthio)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-72-9P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-73-0P, N-(2-Methoxy-5-cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-74-1P, N-(3-(Methoxycarbonyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-75-2P, N-(2-Fluoro-5-cyanophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-76-3P, N-(4-Carboxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-77-4P, N-(2-Fluoro-4-fluorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-78-5P, N-(2-Methyl-3-chlorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-79-6P, N-(2-Fluorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-80-9P, N-(2-Methyl-4-methoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-81-0P, N-(4-(Methylsulfonyl)phenyl)-N-[4-[5-methyl-3-

(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
475573-82-1P, N-(4-(Methoxycarbonyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
475573-83-2P, N-(2-Nitrophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-84-3P,
N-(2-Ethenylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-85-4P, N-(2-Chloro-5-methoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-86-5P, N-(3-Methyl-4-methoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-87-6P, N-(2-(Methylthio)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-88-7P, N-(2,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-89-8P, N-Phenyl-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-90-1P,
N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-91-2P, N-(4-Cyanophenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-92-3P, N-(3-Fluorophenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-93-4P,
N-(4-Fluorophenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-94-5P, N-(3-Methyl-4-cyanophenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-95-6P, N-(3-Fluoro-4-cyanophenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-96-7P, N-(4-(Methylthio)phenyl)-N-[4-[5-methyl-3-(ethylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-97-8P, N-Phenyl-N-[4-[5-methyl-3-((1-methylethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-98-9P,
N-Phenyl-N-[4-[5-methyl-3-((2-methylpropyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475573-99-0P, N-Phenyl-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-00-6P, N-Phenyl-N-[4-[5-methyl-3-(butylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-01-7P,
N-Phenyl-N-[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-02-8P, N-Phenyl-N-[4-[5-methyl-3-(hexylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-03-9P,
N-Phenyl-N-[4-[5-methyl-3-(heptylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-04-0P, N-Phenyl-N-[4-[5-methyl-3-(octylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-05-1P,
N-Phenyl-N-[4-[5-methyl-3-((cyanomethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-06-2P, N-Phenyl-N-[4-[5-methyl-3-((2-methoxyethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-07-3P, N-Phenyl-N-[4-[5-methyl-3-((3,3,3-trifluoropropyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-08-4P, N-Phenyl-N-[4-[5-methyl-3-((cyclopropylmethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-09-5P,
N-Phenyl-N-[4-[5-methyl-3-((acetylmethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-10-8P, N-Phenyl-N-[4-[5-methyl-3-((2-(dimethylamino)ethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-11-9P, N-Phenyl-N-[4-[5-methyl-3-((2-(acetylamino)ethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-12-0P, N-Phenyl-N-[4-[5-methyl-3-((2-((methoxycarbonyl)amino)ethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-13-1P, N-Phenyl-N-[4-[5-methyl-3-((2-acetoxyethyl)thio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-14-2P 475574-15-3P, N-Phenyl-N-[4-[5-methyl-3-(2-butynylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-16-4P, N-(4-Acetylphenyl)-N-[4-[5-methyl-3-(propylthio)-1-


phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-17-5P,
 N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-18-6P, N-(4-Cyanophenyl)-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-19-7P, N-(3-Fluorophenyl)-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-20-0P, N-(4-Fluorophenyl)-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-21-1P, N-(3-Cyano-4-fluorophenyl)-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-22-2P, N-(4-(Methylthio)phenyl)-N-[4-[5-methyl-3-(propylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-23-3P, N-(4-(Dimethylamino)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-24-4P, N-(3-Nitrophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-25-5P, N-(3-(Acetylamino)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-26-6P, N-(3-Aminophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-27-7P, N-(3-Methylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-28-8P, N-(4-Methylphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-29-9P, N-(3-Fluoro-4-cyanophenyl)-N-[4-[5-methyl-3-(butylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-30-2P, N-(3-Fluorophenyl)-N-[4-[5-methyl-3-(butylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-31-3P, N-(4-Cyanophenyl)-N-[4-[5-methyl-3-(butylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-32-4P, N-(3-Methylphenyl)-N-[4-[5-methyl-3-(butylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-33-5P, N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(butylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-34-6P, N-(3-Fluoro-4-cyanophenyl)-N-[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-35-7P, N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-36-8P, N-(3-Fluoro-4-cyanophenyl)-N-[4-[5-methyl-3-(2-methylpropylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-37-9P, N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(2-methylpropylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-39-1P, N-(3-Fluoro-4-cyanophenyl)-N-[4-[5-methyl-3-(2-butynylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-40-4P, N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(2-butynylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-41-5P, N-(3-(Ethoxycarbonyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-42-6P, N-(4-Chlorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-43-7P, N-(3-Chlorophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-44-8P, N-(4-Nitrophenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-45-9P, N-(3-(Benzyloxy)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-46-0P, N-(4-(Benzyloxy)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-47-1P, N-(3-Hydroxyphenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-48-2P, N-(3-(2-Carboxyethyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-49-3P, N-(3-(Carboxymethyl)phenyl)-N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine 475574-50-6P 475574-56-2P, N-(3-(Benzyloxy)phenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-

yl]amine 475574-57-3P, N-(3-Phenoxyphenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
 475574-58-4P, N-(3-Chlorophenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
 475574-59-5P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
 475574-60-8P, N-(3-(Methoxycarbonyl)phenyl)-N-[4-[5-methyl-3-(2-(methylthio)ethyl)-1-phenyl-1H-pyrazol-4-yl]pyrimidin-2-yl]amine
 475574-87-9P 475574-88-0P 475574-89-1P
 475574-90-4P 475574-91-5P 475574-92-6P
 475574-93-7P 475574-94-8P 475574-95-9P
 475575-07-6P, N-Phenyl-N-[4-[5-methyl-3-(propylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-08-7P,
 N-(3-Cyanophenyl)-N-[4-[5-methyl-3-(butylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-09-8P, N-Phenyl-N-[4-[5-methyl-3-(isobutylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 475575-10-1P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(2-(dimethylamino)ethyl)amino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 475575-11-2P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(phenylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-12-3P,
 N-Phenyl-N-[4-[5-methyl-3-(phenylmethyl)amino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-13-4P, N-Phenyl-N-[4-[5-methyl-3-(1-methyl-4-piperidinylamino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 475575-14-5P, N-(3,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-(1-piperidinyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 475575-15-6P, N-(3,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-morpholino-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-16-7P,
 N-(3,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-(3-hydroxy-1-piperidinyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-17-8P,
 N-(3,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-(4-hydroxy-1-piperidinyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-18-9P,
 N-(3,5-Dimethoxyphenyl)-N-[4-[5-methyl-3-(2-hydroxyethyl)amino)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-19-0P,
 N-Phenyl-N-[4-[5-methyl-3-([2-(1H-indol-3-yl)ethyl]amino)]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-20-3P,
 N-(4-Methylphenyl)-N-[4-[5-methyl-3-(2-(dimethylamino)ethoxy)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-21-4P,
 N-Phenyl-N-[4-[5-methyl-3-isobutoxy-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-22-5P, N-(3,4-Dimethoxyphenyl)-N-[4-[5-methyl-3-(phenylmethoxy)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 475575-24-7P, N-Phenyl-N-[4-[5-methyl-3-(butylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-25-8P,
 N-(3-(Phenylmethoxy)phenyl)-N-[4-[5-methyl-3-(methylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-26-9P,
 N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(phenylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-27-0P, N-(3,4-Dimethoxyphenyl)-N-[4-[5-methyl-3-(4-methylphenyl)sulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-28-1P, N-3,4-Dimethoxyphenyl-N-[4-[5-methyl-3-(2-naphthylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine 475575-29-2P, N-Phenyl-N-[4-[5-methyl-3-(butylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 475575-30-5P, N-(3-Methoxyphenyl)-N-[4-[5-methyl-3-(phenylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amine
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Src protein kinase inhibitor; preparation of pyrazolyl pyridinamines and pyrimidinamine inhibitors of protein kinases using condensation, cyclization, and substitution reactions)


RN 475573-43-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-44-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-45-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-46-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475573-47-8 CAPLUS

CN Benzamide, 3-methyl-4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-48-9 CAPLUS

CN Benzonitrile, 3-methyl-4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-49-0 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-50-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluoro-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-51-4 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluoro-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-52-5 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-53-6 CAPLUS

CN Benzonitrile, 3-[[4-[5-ethyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-54-7 CAPLUS

CN Benzoic acid, 3-[[4-[5-ethyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-55-8 CAPLUS

CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-56-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-57-0 CAPLUS

CN Ethanone, 1-[4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475573-58-1 CAPLUS

CN Methanone, [4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]phenyl- (9CI) (CA INDEX NAME)




RN 475573-59-2 CAPLUS

CN Benzamide, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-60-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-61-6 CAPLUS

CN Benzonitrile, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-62-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-ethenylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-63-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[3-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-64-9 CAPLUS

CN Benzonitrile, 2-methyl-4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-65-0 CAPLUS

CN Ethanone, 1-[3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475573-66-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-ethyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(2-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-68-3 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-69-4 CAPLUS

CN 2-Pyrimidinamine, N-[1,1'-biphenyl]-4-yl-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-70-7 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-71-8 CAPLUS

CN 2-Pyrimidinamine, N-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-72-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-73-0 CAPLUS

CN Benzonitrile, 4-methoxy-3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-74-1 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 475573-75-2 CAPLUS

CN Benzonitrile, 4-fluoro-3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-76-3 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-77-4 CAPLUS

CN 2-Pyrimidinamine, N-(2,4-difluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-78-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-chloro-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-79-6 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-80-9 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-2-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-81-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-82-1 CAPLUS

CN Benzoic acid, 4-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 475573-83-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 475573-84-3 CAPLUS

CN 2-Pyrimidinamine, N-(2-ethenylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-85-4 CAPLUS

CN 2-Pyrimidinamine, N-(2-chloro-5-methoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-86-5 CAPLUS

CN 2-Pyrimidinamine, N-(4-methoxy-3-methylphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-87-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-88-7 CAPLUS

CN 2-Pyrimidinamine, N-(2,5-dimethoxyphenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475573-89-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-90-1 CAPLUS

CN Benzonitrile, 3-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-91-2 CAPLUS

CN Benzonitrile, 4-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475573-92-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 475573-93-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 475573-94-5 CAPLUS


CN Benzonitrile, 4-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-methyl- (9CI) (CA INDEX NAME)




RN 475573-95-6 CAPLUS
 CN Benzonitrile, 4-[[4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)



RN 475573-96-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[3-(ethylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475573-97-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-methyl-3-[(1-methylethyl)thio]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-98-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(2-methylpropyl)thio]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475573-99-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-00-6 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-01-7 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




Me-(CH₂)₄-S

RN 475574-02-8 CAPLUS
 CN 2-Pyrimidinamine, 4-[3-(hexylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




Me-(CH₂)₅-S

RN 475574-03-9 CAPLUS
 CN 2-Pyrimidinamine, 4-[3-(heptylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



Me-(CH₂)₆-S


RN 475574-04-0 CAPLUS
 CN 2-Pyrimidinamine, 4-[5-methyl-3-(octylthio)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



Me-(CH₂)₇-S

RN 475574-05-1 CAPLUS


CN Acetonitrile, [[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]- (9CI) (CA INDEX NAME)



NC-CH₂-S

RN 475574-06-2 CAPLUS


CN 2-Pyrimidinamine, 4-[3-[(2-methoxyethyl)thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



MeO-CH₂-CH₂-S

RN 475574-07-3 CAPLUS


CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(3,3,3-trifluoropropyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



F₃C-CH₂-CH₂-S


RN 475574-08-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(cyclopropylmethyl)thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-09-5 CAPLUS

CN 2-Propanone, 1-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]- (9CI) (CA INDEX NAME)




RN 475574-10-8 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[[2-(dimethylamino)ethyl]thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475574-11-9 CAPLUS


CN Acetamide, N-[2-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]ethyl]- (9CI) (CA INDEX NAME)



AcNH-CH₂-CH₂-S

RN 475574-12-0 CAPLUS


CN Carbamic acid, [2-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]ethyl]-, methyl ester (9CI) (CA INDEX NAME)



MeO-C(=O)-NH-CH₂-CH₂-S

RN 475574-13-1 CAPLUS

CN Ethanol, 2-[[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]thio]-, acetate (ester) (9CI) (CA INDEX NAME)




AcO-CH₂-CH₂-S

RN 475574-14-2 CAPLUS


CN D-Cysteine, S-[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475574-15-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(2-butynylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-16-4 CAPLUS

CN Ethanone, 1-[4-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475574-17-5 CAPLUS


CN Benzonitrile, 3-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-18-6 CAPLUS
 CN Benzonitrile, 4-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 475574-19-7 CAPLUS
 CN 2-Pyrimidinamine, N-(3-fluorophenyl)-4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-20-0 CAPLUS
 CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-21-1 CAPLUS

CN Benzonitrile, 2-fluoro-5-[[4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-22-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(propylthio)-1H-pyrazol-4-yl]-N-[4-(methylthio)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-23-3 CAPLUS

CN 1,4-Benzenediamine, N,N-dimethyl-N'-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 475574-24-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 475574-25-5 CAPLUS

CN Acetamide, N-[3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 475574-26-6 CAPLUS

CN 1,3-Benzenediamine, N-[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 475574-27-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475574-28-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475574-29-9 CAPLUS

CN Benzonitrile, 4-[[4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 475574-30-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 475574-31-3 CAPLUS

CN Benzonitrile, 4-[[4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-32-4 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475574-33-5 CAPLUS

CN Benzonitrile, 3-[[4-[3-(butylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-34-6 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-35-7 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-(pentylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-36-8 CAPLUS

CN Benzonitrile, 2-fluoro-4-[[4-[5-methyl-3-[(2-methylpropyl)thio]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-37-9 CAPLUS

CN Benzonitrile, 3-[[4-[5-methyl-3-[(2-methylpropyl)thio]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-39-1 CAPLUS

CN Benzonitrile, 4-[[4-[3-(2-butynylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-2-fluoro- (9CI) (CA INDEX NAME)




RN 475574-40-4 CAPLUS

CN Benzonitrile, 3-[[4-[3-(2-butynylthio)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-41-5 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 475574-42-6 CAPLUS

CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-43-7 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-44-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-(4-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 475574-45-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-46-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-N-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-47-1 CAPLUS

CN Phenol, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475574-48-2 CAPLUS

CN Benzenepropanoic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 475574-49-3 CAPLUS


CN Benzeneacetic acid, 3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 475574-50-6 CAPLUS


CN D-Valine, N-[3-[3-[[4-[5-methyl-3-(methylthio)-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]phenyl]-1-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 475574-56-2 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475574-57-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-N-(3-phenoxyphenyl)- (9CI) (CA INDEX NAME)




RN 475574-58-4 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-59-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475574-60-8 CAPLUS

CN Benzoic acid, 3-[[4-[5-methyl-3-[2-(methylthio)ethyl]-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 475574-87-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(phenylthio)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-88-0 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(phenylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-89-1 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(1-phenylethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-90-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(2-pyridinylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-91-5 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[(1,3-dioxan-2-ylmethyl)thio]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-92-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(2-thienylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-93-7 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(1-methyl-4-piperidinyl)thio]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-94-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(3-pyridinylthio)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475574-95-9 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(2-thiazolylmethyl)thio]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-07-6 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-(propylamino)-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-08-7 CAPLUS

CN Benzonitrile, 3-[[4-[3-(butylamino)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)




RN 475575-09-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(2-methylpropyl)amino]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-10-1 CAPLUS

CN 1,2-Ethanediamine, N'-[4-[2-[(3-methoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 475575-11-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylamino)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-12-3 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-1-phenyl-3-[(phenylmethyl)amino]-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-13-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-[(1-methyl-4-piperidinyl)amino]-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-14-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-methyl-1-phenyl-3-(1-piperidinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-15-6 CAPLUS

CN 2-Pyrimidinamine, N-(3,5-dimethoxyphenyl)-4-[5-methyl-3-(4-morpholinyl)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-16-7 CAPLUS

CN 3-Piperidinol, 1-[4-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 475575-17-8 CAPLUS

CN 4-Piperidinol, 1-[4-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 475575-18-9 CAPLUS

CN Ethanol, 2-[[4-[2-[(3,5-dimethoxyphenyl)amino]-4-pyrimidinyl]-5-methyl-1-phenyl-1H-pyrazol-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 475575-19-0 CAPLUS

CN 1H-Indole-3-ethanamine, N-[5-methyl-1-phenyl-4-[2-(phenylamino)-4-pyrimidinyl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 475575-20-3 CAPLUS

CN 2-Pyrimidinamine, 4-[3-[2-(dimethylamino)ethoxy]-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 475575-21-4 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(2-methylpropoxy)-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-22-5 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylmethoxy)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-24-7 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(butylsulfonyl)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)




RN 475575-25-8 CAPLUS

CN 2-Pyrimidinamine, 4-[5-methyl-3-(methanesulfonyl)-1-phenyl-1H-pyrazol-4-yl]-N-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 475575-26-9 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylsulfonyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-27-0 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-3-[(4-methylphenyl)sulfonyl]-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)




RN 475575-28-1 CAPLUS

CN 2-Pyrimidinamine, N-(3,4-dimethoxyphenyl)-4-[5-methyl-3-(2-naphthalenylsulfonyl)-1-phenyl-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 475575-29-2 CAPLUS


CN 2-Pyrimidinamine, 4-[3-(butylsulfinyl)-5-methyl-1-phenyl-1H-pyrazol-4-yl]-N-phenyl- (9CI) (CA INDEX NAME)



RN 475575-30-5 CAPLUS

CN 2-Pyrimidinamine, N-(3-methoxyphenyl)-4-[5-methyl-1-phenyl-3-(phenylsulfinyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

10/520,567



L8 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2002:449675 CAPLUS
 DN 137:33311
 TI Preparation of pyrazolylpyridine- and -pyrimidineamines as JNK inhibitors
 IN Ledebøer, Mark; Salituro, Francesco; Moon, Young-Choon
 PA Vertex Pharmaceuticals Incorporated, USA
 SO PCT Int. Appl., 62 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046184	A1	20020613	WO 2001-US46383	20011205
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2430539	A1	20020613	CA 2001-2430539	20011205
	AU 200228783	A	20020618	AU 2002-28783	20011205
	US 2002111353	A1	20020815	US 2001-5133	20011205
	EP 1343781	A1	20030917	EP 2001-989898	20011205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004518644	T	20040624	JP 2002-547922	20011205
	MX 2003PA05001	A	20030905	MX 2003-PA5001	20030605
PRAI	US 2000-251409P	P	20001205		
	WO 2001-US46383	W	20011205		

OS MARPAT 137:33311

AB Title compds. (I; R = H or alkyl; R1 = cycloalkyl, Ph, pyridyl, etc.; R2 = H, alkoxymethyl, heterocyclylmethyl, etc.; R3 = Ph, CH2Ph, etc.; Z1 = pyridine- or pyrimidine-4,2-diyl) were prepared. Thus, R4Z1CH(CHO)2 (R4 = MeS, Z1 = pyrimidine-2,4-diyl) was cyclocondensed with H2NNHC6H3F2-2,4 and the S-oxidized product aminated by cyclohexylamine to give I (R = R2 = H, R1 = cyclohexyl, R3 = C6H3F2-2,4). Data for biol. activity of I were given.


IT 434283-95-1P 434283-96-2P 434284-01-2P
 434284-02-3P 434284-03-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolylpyridine- and -pyrimidineamines as JNK inhibitors)


RN 434283-95-1 CAPLUS

CN 2-Pyrimidinamine, 4-(3-methyl-1-phenyl-1H-pyrazol-4-yl)-N-phenyl- (9CI)
 (CA INDEX NAME)




RN 434283-96-2 CAPLUS

CN Benzenesulfonamide, 4-[[4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-2-pyrimidinyl]amino]- (9CI) (CA INDEX NAME)



RN 434284-01-2 CAPLUS


CN 2-Pyrimidinamine, N-(4-fluorophenyl)-4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)



RN 434284-02-3 CAPLUS


CN 2-Pyrimidinamine, N-(4-chlorophenyl)-4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

10/520,567



RN 434284-03-4 CAPLUS


CN 2-Pyrimidinamine, 4-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-N-(4-nitrophenyl)-
(9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2001:617995 CAPLUS
 DN 135:180783
 TI Preparation of arylaminopyrimidines as Kinase inhibitors
 IN Armistead, David M.; Bemis, Jean E.; Di Pietro, Lucian V.; Geuns-Meyer, Stephanie D.; Habgood, Gregory J.; Kim, Joseph L.; Nunes, Joseph J.; Patel, Vinod F.; Toledo-Sherman, Leticia M.
 PA Amgen Inc., USA
 SO PCT Int. Appl., 91 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001060816	A1	20010823	WO 2001-US4983	20010216
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2400447	A1	20010823	CA 2001-2400447	20010216
	US 2002052386	A1	20020502	US 2001-785599	20010216
	US 2003004174	A9	20030102		
	EP 1257546	A1	20021120	EP 2001-909266	20010216
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003532635	T	20031105	JP 2001-560200	20010216
	HU 200301117	A2	20031229	HU 2003-1117	20010216
	ZA 2002006386	A	20031126	ZA 2002-6386	20020812
	MX 2002PA07957	A	20021129	MX 2002-PA7957	20020815
	US 2003199534	A1	20031023	US 2003-353507	20030128
	US 2005203114	A1	20050915	US 2005-125614	20050509
PRAI	US 2000-183256P	P	20000217		
	US 2001-785599	A	20010216		
	WO 2001-US4983	W	20010216		
	US 2003-353507	A1	20030128		
OS	MARPAT 135:180783				
AB	Arylaminoypyrimidines I wherein R1 and R2 are independently aryl, 5-8 membered monocyclic, 11-14 membered bicyclic, 1-9-heteroatoms tricyclic, substituted amine, sulfide, alkoxy, acyl, heterocycle, were prepared as Kinase inhibitors useful for treating disease or disease symptoms. Thus, pyrimidine II was prepared and tested in vitro as kinases inhibitor (FGFR1-1, IC50 < 1.5 μ M).				
IT	354817-35-9P 354817-36-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (Preparation of triazine Kinase inhibitors)				
RN	354817-35-9 CAPLUS				
CN	2-Pyrimidinamine, 4-[3-(4-chlorophenyl)-1H-pyrazol-1-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)				



RN 354817-36-0 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-methoxyphenyl)-1H-pyrazol-1-yl]-N-(3,4,5-trimethoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2000:368337 CAPLUS
 DN 133:4656
 TI Preparation of heteroarylpyrazoles as p38 kinase inhibitors
 IN Anantanarayan, Ashok; Clare, Michael; Collins, Paul W.; Crich, Joyce Z.;
 Devraj, Rajesh; Flynn, Daniel L.; Geng, Lifeng; Graneto, Matthew J.;
 Hanau, Cathleen E.; Hanson, Gunnar J.; Hartmann, Susan J.; Hepperle,
 Michael; Huang, He; Khanna, Ish K.; Koszyk, Francis J.; Liao, Shuyuan;
 Metz, Suzanne; Partis, Richard A.; Perry, Thao D.; Rao, Shashidhar N.;
 Selness, Shaun Raj; South, Michael S.; Stealey, Michael A.; Talley, John
 Jeffrey; Vazquez, Michael L.; Weier, Richard M.; Xu, Xiangdong; Yu, Yi
 PA G.D. Searle and Co., USA
 SO PCT Int. Appl., 1210 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 5


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000031063	A1	20000602	WO 1999-US26007	19991117
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,				
	CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,				
	IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,				
	MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,				
	SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6514977	B1	20030204	US 1998-196623	19981120
	CA 2351725	A1	20000602	CA 1999-2351725	19991117
	EP 1144403	A1	20011017	EP 1999-965756	19991117
	EP 1144403	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	BR 9915420	A	20020122	BR 1999-15420	19991117
	EE 200100268	A	20021216	EE 2001-268	19991117
	NZ 512344	A	20031128	NZ 1999-512344	19991117
	AU 774262	B2	20040624	AU 2000-21454	19991117
	AT 278685	T	20041015	AT 1999-965756	19991117
	ES 2229809	T3	20050416	ES 1999-965756	19991117
	US 6525059	B1	20030225	US 2000-513351	20000224
	MX 2001PA05043	A	20010710	MX 2001-PA5043	20010518
	NO 2001002456	A	20010719	NO 2001-2456	20010518
	BG 105620	A	20020131	BG 2001-105620	20010619
	HK 1040705	A1	20050304	HK 2002-102213	20020322
	AU 2003200580	A1	20030501	AU 2003-200580	20030217
PRAI	US 1998-196623	A	19981120		
	US 1997-47570P	P	19970522		
	AU 1998-75883	A3	19980522		
	US 1998-83670	A2	19980522		
	WO 1999-US26007	W	19991117		
OS	MARPAT 133:4656				
AB	Title compds. [I; R1 = H, OH, NH2, (cyclo)alk(en)yl, acyl, aryl, etc.; R2 = H, halo, alkyl, alkoxy, (un)substituted piperidiny, etc.; R3 = pyridyl, pyrimidinyl, quinolyl, etc.; R4 = H, alkyl, heterocyclyl, aryl, etc.] were prepared by reaction of ketones with hydrazines. Thus, R3CH2C(=O)Me (R3 = 4-pyridinyl) was condensed with 3,4-F(MeO)C6H3CHO and the product cyclocondensed with TsNHNH2 to give title compound II. Data for biol. activity of I were given.				
IT	271574-63-1P 271574-64-2P				

10/520,567

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylpyrazole p38 kinase inhibitors by cyclocondensation of hydrazines with ketones)


RN 271574-63-1 CAPLUS

CN 2-Pyrimidinamine, N-(2-fluorophenyl)-4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)



RN 271574-64-2 CAPLUS

CN 2-Pyrimidinamine, 4-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-N-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/520,567

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

90.53

309.34

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-13.26

-13.26

STN INTERNATIONAL LOGOFF AT 18:24:57 ON 15 SEP 2007